CN108239076A - Quinazoline compounds and preparation method thereof, purposes and pharmaceutical composition - Google Patents

Quinazoline compounds and preparation method thereof, purposes and pharmaceutical composition Download PDF

Info

Publication number
CN108239076A
CN108239076A CN201611214102.9A CN201611214102A CN108239076A CN 108239076 A CN108239076 A CN 108239076A CN 201611214102 A CN201611214102 A CN 201611214102A CN 108239076 A CN108239076 A CN 108239076A
Authority
CN
China
Prior art keywords
alkyl
compound
amino
bases
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201611214102.9A
Other languages
Chinese (zh)
Other versions
CN108239076B (en
Inventor
许恒
陈晓光
林松文
季鸣
金晶
吴德雨
王春阳
吕元皓
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Materia Medica of CAMS
Original Assignee
Institute of Materia Medica of CAMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201611214102.9A priority Critical patent/CN108239076B/en
Application filed by Institute of Materia Medica of CAMS filed Critical Institute of Materia Medica of CAMS
Priority to CA3174890A priority patent/CA3174890A1/en
Priority to AU2017389818A priority patent/AU2017389818B2/en
Priority to EP22213583.2A priority patent/EP4169917A1/en
Priority to EP17886474.0A priority patent/EP3560921A4/en
Priority to PCT/CN2017/118771 priority patent/WO2018121550A1/en
Priority to JP2019534817A priority patent/JP7077323B2/en
Priority to CN201780075753.0A priority patent/CN110382490A/en
Priority to CA3048546A priority patent/CA3048546A1/en
Priority to EP22213594.9A priority patent/EP4169918A1/en
Priority to CA3174865A priority patent/CA3174865A1/en
Priority to US16/473,901 priority patent/US11534443B2/en
Publication of CN108239076A publication Critical patent/CN108239076A/en
Publication of CN108239076B publication Critical patent/CN108239076B/en
Application granted granted Critical
Priority to AU2022202886A priority patent/AU2022202886B2/en
Priority to AU2022202885A priority patent/AU2022202885B2/en
Priority to JP2022081738A priority patent/JP7384536B2/en
Priority to JP2022081736A priority patent/JP7384535B2/en
Priority to US17/944,149 priority patent/US20230110550A1/en
Priority to US17/944,151 priority patent/US20230113478A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to quinazoline compounds and preparation method thereof, purposes and pharmaceutical compositions.The quinazoline compounds are by formula (I) Suo Shi, it is 3 kinases of phosphatidylinositols (PI3K) inhibitor, can be used for preventing and/or treat with the relevant disease of PI3K activity, such as cancer, immunity disease, angiocardiopathy, viral infection, inflammation, metabolism/endocrine dysfunction or neurological disease.

Description

Quinazoline compounds and preparation method thereof, purposes and pharmaceutical composition
Technical field
The invention belongs to pharmaceutical technology fields, are related to a kind of quinazoline compounds and preparation method thereof, purposes and drug Composition.
Background technology
Phosphatidyl-inositol 3-kinase (phosphatidylinositol 3-kinase, PI3K) belongs to lipid kinase family, Participate in the multiple functions such as proliferation, differentiation, apoptosis and the glucose transport of cell.According to its structure, adjustment effect and lipid bottom The difference of object specificity, PI3K are divided into three categories (I, II and III).That research is the most deep at present is I class PI3K, sub- by adjusting Base (p85) and catalytic subunit (p110) are formed, and are heterodimer.I classes PI3K includes 4 hypotypes, wherein PI3K α and PI3K β Two hypotypes are widely present in various types of cells, and another two hypotype PI3K δ and PI3K γ are then mainly distributed in leucocyte (Vanhaesebroeck etc., Trends Biochem Sci., 2005,30 (4)：194-204).As receptor tyrosine kinase (RTK) and the major downstream effector of g protein coupled receptor (GPCR), PI3K can activate serine/threonine egg by generation The phosphatide of white kinases (protein kinase B, AKT) and other downstream effectors, will come from various growth factors and cell because The signal transduction of son is to intracellular.Exception/the overacfivity for the signal path that PI3K is mediated is related to a variety of diseases.Such as PI3K has generation, the evolution of tumour critical effect, particularly encodes the gene PIK3CA of p110 α most Such as breast cancer, lung cancer, intestinal cancer, oophoroma, incidence cancer, gastric cancer, prostate cancer, the cancer of the brain, liver cancer, tumor in digestive tract in number tumour With the appearance such as leukaemia largely amplification and variation (Zhao etc., Nat.Drug Discov.Rev.2009,8:627-644).2014 PI3K δ inhibitor Idelalisib (Gilead) are had approved in year FDA for treating chronic lymphocytic leukemia (CLL), recurrence Property follicular B cells non-Hodgkin lymphoma (FL) and recurrent small lymphocyte lymthoma (SLL).Also some PI3K inhibitor The clinical test of anti-tumor aspect is being carried out, such as BKM120 (Novartis, III phase), BAY 80-6946 (Bayer, III Phase), PF-05212384 (Pfizer, II phase) etc..In addition to tumour, I classes PI3K to inflammation, immunity disease, angiocardiopathy, Virus infection, metabolism/endocrine dysfunction and neurological disease also have important adjustment effect, some compounds are such as GSK2269557 (chronic obstructive pulmonary disease, clinical II phases), GSK2126458 (idiopathic pulmonary fibrosis, clinical I phase), UCB- 5857 (primary Sjogren's syndrome, clinical II phases) and RV-1729 (chronic obstructive pulmonary disease, clinical I phase) etc. are directed to these diseases Disease has entered clinical experimental stage.
PI3K has become the drug targets to have a great attraction, but also needs to research and develop safer and more effective PI3K inhibitor For prevention and/or treating cancer, immunity disease, angiocardiopathy, viral infection, inflammation, metabolism/endocrine dysfunction Or neurological disease.
Invention content
The object of the present invention is to provide a kind of new PI3K inhibitor, to I class PI3K, including PI3K α, PI3K β, PI3K γ and/or PI3K δ, particularly PI3K α have stronger inhibitory activity, thus to the disease mediated by PI3K, such as cancer, immunity Disease, angiocardiopathy, viral infection, inflammation, metabolism/endocrine dysfunction or neurological disease have preferably prevent and/ Or therapeutic effect.
On the one hand, the present invention provides a kind of formula (I) compound represented, its stereoisomer, geometric isomer, changes Isomers or pharmaceutically acceptable salt：
Wherein
R1For C1-3Alkyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R2Selected from hydrogen, C1-3Alkyl, C1-3Alkoxy, 3-7 members cycloalkyl or 3-7 membered heterocycloalkyls, wherein the C1-3Alkane Base, C1-3Alkoxy, 3-7 members cycloalkyl or 3-7 membered heterocycloalkyls are optionally replaced by one or more Rb；
Rb is selected from halogen, cyano, hydroxyl, trifluoromethyl, C1-3Alkyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl ammonia Base or two (C1-3Alkyl) amino；
R3Selected from C1-3Alkoxy, halogen or C1-3Alkyl；
R4Selected from C1-3Alkyl, 3-7 members cycloalkyl, aryl or heteroaryl, wherein the aryl and heteroaryl are optionally by one It is a or multiple selected from following group substitution：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, trifluoro Methyl, difluoromethyl, cyano or C1-3Alkoxy.
Preferably, the present invention provides a kind of formula (II) compound represented, its stereoisomer, geometric isomer, mutually Tautomeric or pharmaceutically acceptable salt：
Wherein
R1For C1-3Alkyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R3Selected from methoxyl group, chlorine or methyl；
R4Selected from C1-3Alkyl, 3-7 members cycloalkyl, phenyl or thienyl, wherein the phenyl and thienyl are optionally by one It is a or multiple selected from following group substitution：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, trifluoro Methyl, difluoromethyl, cyano or C1-3Alkoxy；
Ring A is selected from 3-7 members cycloalkyl or 3-7 membered heterocycloalkyls；
R5Selected from C1-3Alkyl, halogen, cyano, trifluoromethyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl amino or Two (C1-3Alkyl) amino；
M is 0,1,2,3 or 4；When m is 2,3 or 4, R5It can be identical or different group.
It is further preferred that the present invention provides compound, its stereoisomer, geometrical isomerisms shown in a kind of formula (II) Body, tautomer or pharmaceutically acceptable salt：
Wherein
R1For methyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R3For methoxyl group；
R4Selected from phenyl or thienyl, wherein the phenyl and thienyl are optionally selected from following base by one or more Group's substitution：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, trifluoromethyl, difluoromethyl, cyano or C1-3Alkoxy；
Ring A is 3-7 member cycloalkyl；
R5Selected from C1-3Alkyl, halogen, cyano, trifluoromethyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl amino or Two (C1-3Alkyl) amino；
M is 0,1,2,3 or 4；When m is 2,3 or 4, R5It can be identical or different group.
It is further preferred that the present invention provides compound, its stereoisomer, geometrical isomerisms shown in a kind of formula (II) Body, tautomer or pharmaceutically acceptable salt：
Wherein
R1For methyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R3For methoxyl group；
R4Selected from phenyl or thienyl, wherein the phenyl and thienyl are optionally selected from following base by one or more Group's substitution：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, trifluoromethyl, difluoromethyl, cyano or C1-3Alkoxy；
Ring A is 3-7 membered heterocycloalkyls；
R5Selected from C1-3Alkyl, halogen, cyano, trifluoromethyl, C1-3Alkoxy, C1-3Alkyl hydroxy, C1-3Alkyl amino or Two (C1-3Alkyl) amino；
M is 0,1,2,3 or 4；When m is 2,3 or 4, R5It can be identical or different group.
It is further preferred that the present invention provides compound, its stereoisomer, geometrical isomerisms shown in a kind of formula (II) Body, tautomer or pharmaceutically acceptable salt：
Wherein
R1For methyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R3For methoxyl group；
R4Selected from phenyl or thienyl, wherein the phenyl and thienyl are optionally selected from following base by one or more Group's substitution：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, trifluoromethyl, difluoromethyl, cyano or C1-3Alkoxy；
Ring A is selected from：
R5Selected from C1-3Alkyl, halogen, cyano, trifluoromethyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl amino or Two (C1-3Alkyl) amino；
M is 0,1,2,3 or 4；When m is 2,3 or 4, R5It can be identical or different group.
Specifically, it is as follows according to currently preferred compound：
On the other hand, the present invention also provides the compound, its stereoisomer, geometric isomer, tautomers Preparation method, include the following steps：
(1) using compound A as starting material, by bromo-reaction prepare compound B；
(2) compound C is obtained by the reaction with triphosgene in compound B；
(3) compound C and N, O- dimethyl hydroxylamine hydrochloride reaction prepare compound D；
(4) compound E is obtained by methyl-magnesium-bromide attack by compound D；
(5) compound E obtains the compound F with quinazoline skeleton with ammonium formate and formamide；
(6) compound F reacts removing methyl with alchlor, obtains versatile intermediates G；
(7) intermediate G is reacted with alcohol generation Mitsunobu or is reacted with halides, obtains compound H；
(8) under Suzuki reaction conditions, the pyridine -3- pinacol borates of compound H and substitution are coupled to obtain described Compound, its stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt；Or compound H is with joining Pinacol borate is obtained by the reaction corresponding pinacol borate, then is coupled with substituted 3- bromopyridines to obtain the chemical combination Object, its stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt.
In another aspect, the present invention also provides a kind of pharmaceutical composition, described pharmaceutical composition include the compound, its Stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt and optional pharmaceutically acceptable load Body and/or excipient；Preferably, described pharmaceutical composition is also included except the compound, its stereoisomer, geometrical isomerism One or more preventions and/or treating cancer, immunity disease except body, tautomer or pharmaceutically acceptable salt, Angiocardiopathy, viral infection, inflammation, metabolism/endocrine dysfunction or neurological disease active constituents of medicine；Preferably, Described pharmaceutical composition is to be pharmaceutically acceptable for prevention and/or treating cancer, immunity disease, angiocardiopathy, disease Malicious infection, inflammation, metabolism/endocrine dysfunction or neurological disease pharmaceutical preparation.
Another aspect, the present invention also provides a kind of pharmaceutical preparations, and it includes at least one compound, its solids Isomers, geometric isomer, tautomer or pharmaceutically acceptable salt and optional pharmaceutically acceptable carrier or/ Or excipient；Preferably, the pharmaceutical preparation is selected from following pharmaceutical dosage form：Parenteral formulation, such as inject solution Or suspension；Enteral drug-delivery preparation, such as oral preparation, such as tablet or capsule；Local administration preparation, for example, lotion, gel, Ointment, emulsion, pernasal preparation, suppository, percutaneous drug administration preparation or eye-drops preparations.
Another aspect, the present invention also provides the compound, its stereoisomer, geometric isomer, tautomers Or pharmaceutically acceptable salt or described pharmaceutical composition prepare for prevent and/or treating cancer, immunity disease, Angiocardiopathy, viral infection, inflammation, metabolism/endocrine dysfunction or neurological disease drug in purposes.In other words, The present invention provides a kind of prevention and/or treating cancer, immunity disease, angiocardiopathy, viral infection, inflammation, metabolism/interior The method of secretory functional disturbance or neurological disease, this method include giving subject's prevention in need and/or therapeutically effective amount The compound, its stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable salt or the medicine Compositions.
Part term used in the present invention is defined as follows below, other undefined terms have technical field Meaning well known to technical staff.
Halogen refers to fluorine, chlorine, bromine or iodine.
C1-3Alkylidene refers to the linear chain or branch chain bivalent hydrocarbon radical with the saturation of 1-3 carbon atom.The example of such group Including but not limited to：Methylene (- CH2), ethylidene (- CH2CH2), propylidene (- CH2CH2CH2-)。
C1-3Alkyl refers to the straight chain and attachment radical of saturated aliphatic alkyl group with 1 to 3 carbon atom.The example of such group Including but not limited to：Methyl, ethyl, propyl, isopropyl.
3-7 member cycloalkyl refers to the monocyclic, condensed of the saturation with 3 to 7 carboatomic ring atoms, loop coil or multiring structure.It is such The example of group includes but not limited to：Cyclopropyl, cyclobutyl, cyclopenta, cyclopentenyl, cyclohexyl and suberyl.
3-7 membered heterocycloalkyls refer to that saturation with 3 to 7 annular atoms or part are unsaturated (there are one having i.e. in ring Or multiple double bonds and/or three key) carbon ring group, wherein one or more annular atoms are selected from nitrogen, oxygen or S (O)m(wherein m is 0 Integer to 2) hetero atom, but do not include the loop section of-O-O- ,-O-S- or-S-S-, remaining annular atom is carbon.3-7 members are satisfied It is included but are not limited to the specific example of Heterocyclylalkyl：Oxirane base, aziridine base, azetidinyl, oxygen Azetidinyl, Thietane base, dihydrofuran base, tetrahydrofuran base, tetrahydro-thienyl, pyrrolidinyl, imidazolidinyl, pyrrole Oxazolidinyl, oxazole alkyl, isoxazole alkyl, thiazolidinyl, isothiazole alkyl, 1,4- dioxanes base, 1,3- dioxas Cyclohexyl, 1,3- dithians base, piperidyl, morpholinyl, piperazinyl, dihydro pyranyl, THP trtrahydropyranyl, tetrahydrochysene thiophene It mutters base etc.；It is preferred that oxetanyl, tetrahydrofuran base, THP trtrahydropyranyl, piperidyl, morpholinyl, piperazinyl.
C1-3Alkoxy refers to O- alkyl, and wherein the alkyl contains 1 to 3 carbon atom and is straight chain, branch or ring-type.This The example of class group includes but not limited to：Methoxyl group, ethyoxyl, positive propoxy, isopropoxy or ring propoxyl group.
Aryl refers to monocyclic or bicyclic aromatic carbocylic groups, usually have 6-10 carbon atom, such as phenyl or Naphthalene.It is preferred that phenyl.
Heteroaryl refers to monocyclic 5- or 6- member aromatic heterocycle bases, including but not limited to：5- unit's heteroaryls：Furyl, Thienyl, pyrrole radicals, oxazolyl, isoxazolyls, thiazolyl, isothiazolyl, imidazole radicals, pyrazolyl, triazolyl (1,2,4- triazoles Base, 1,3,4- triazolyls or 1,2,3- triazolyls), thiadiazolyl group (1,3,4- thiadiazolyl groups, 1,2,5- thiadiazolyl groups, 1,2,3- Thiadiazolyl group or 1,2,4- thiadiazolyl groups) are He oxadiazolyl (1,3,4- oxadiazolyls, 1,2,5- oxadiazolyls, 1,2,3- Evil bis- Oxazolyl or 1,2,4- oxadiazolyls) and 6- unit's heteroaryls：Pyridyl group, pyrimidine radicals, pyrazinyl and pyridazinyl and bicyclic group Group, such as benzofuranyl, benzothienyl, indazolyl, purine radicals, quinolyl, isoquinolyl, phthalazinyl, naphthyridines base, quinoline Quinoline base (chinocalinyl), quinazolyl, cinnoline base, pteridyl, indolizine base, indyl, isoindolyl.Preferred heteroaryl Group is thienyl, thiazolyl, pyridyl group, pyrimidine radicals.
Singly-bound refers to that two groups of its connection are connected directly, for example when L represents singly-bound in O-L-R represents structure reality On be O-R.
" optionally " mean event described later or environment can with but need not occur, the explanation include the event or Environment generation or not spot occasion.For example, " alkyl being optionally optionally substituted by halogen " mean halogen can with but necessarily deposit Include the situation that alkyl is optionally substituted by halogen and the situation that alkyl is not optionally substituted by halogen in, the explanation.
If group, such as " R5" be portrayed as in formula " floating " " on ring system A：
Refer to " R5" any atom of ring system is attributable to, as long as forming rock-steady structure, it is believed that an annular atom in annular atom On be depicted, imply or clearly defined hydrogen is substituted.
Compound of the present invention can contain one or more chiral centres, be deposited with different stereoisomeric forms in any ratio .All stereoisomeric forms in any ratio of the compounds of this invention, including but not limited to diastereoisomer, enantiomter and resistance turn different Structure body and their mixture (such as racemic mixture) are within the scope of the present invention.
Compound of the present invention includes its geometric isomer.For example, if the compound of the present invention contains double bond Or geometric isomer may be present in condensed ring, these compounds, then the mixture of the cis- of them, trans forms and cis and trans It is included within the scope of the present invention.
Compound of the present invention includes its tautomer.Tautomer refers to what is mutually converted via low energy barrier The constitutional isomer of different-energy, such as keto-enol and imine-enamine tautomerism.
Compound of the present invention further includes its compound isotopically labelled, wherein one or more atoms are naturally sent out Existing have same atoms ordinal number but the atom of different atomic masses or mass number substitutes.Example includes but not limited to：Hydrogen is same Position element2H and3H；Carbon isotope11C、13C and14C；Chlorine isotope36Cl；Fluorine isotope18F；Iodine isotope123I and125I；The same position of nitrogen Element13N and15N；Oxygen isotope15O、17O and18O；Phosphorus isotope32P and sulfur isotope35S。
The various hydrates and solvate and its polymorphic of compound or its salt of the present invention (polymorphisms) it is intended to be included within the scope of the present invention.
The prodrug of compound of the present invention is intended to be included within the scope of the present invention.Certain of compound of the present invention A little derivatives itself have weaker pharmacological activity or a no pharmacological activity, but when these derivatives are given in vivo or to on body When, they can be converted to the compound of the present invention with pharmacological activity for example, by modes such as hydrolytic cleavages, these Derivative is known as " prodrug ".Further information about prodrug purposes can be in Pro-drugs as Novel Delivery Systems, Vol.14, ACS Symposium Series (T.Higuchi and W.Stella) and Bioreversible Carriers in Drug Design,Pergamon Press,1987(ed.E.B.Roche,American Pharmaceutical Association) in find.
Compound of the present invention includes its pharmaceutically acceptable salt.Pharmaceutically acceptable salt refers to for pharmacy Salt upper acceptable and that there is the pharmacological activity needed for parent compound.Berge et al. is in J.Pharma.Sci., and 1977, Pharmaceutically acceptable salt is described in detail in 66,1-19, the document is incorporated herein by reference.Institute of the present invention The compound stated can contain enough acidic-groups, enough basic groups or the functional group for having both both types, and Correspondingly pharmaceutically acceptable salt is formed with some inorganic or organic bases or inorganic and organic acid reaction.It is pharmaceutically acceptable Salt example include sulfate, pyrosulfate, disulfate, sulphite, bisulfites, phosphate, single hydrogen orthophosphate, It is dihydrogen orthophosphate, metaphosphate, pyrophosphate, hydrochloride, hydrobromate, hydriodate, acetate, propionate, caprate, pungent Hydrochlorate, acrylates, formates, isobutyrate, caproate, enanthate, propiolate, oxalates, malonate, succinic acid Salt, suberate, sebacate, fumarate, maleate, butine -1,4- diacid salts, hexin -1,6- diacid salts, benzoic acid Salt, chloro-benzoate, methyl benzoic acid salt, dinitro-benzoate, hydroxy benzoate, methoxy benzoic acid salt, adjacent benzene Diformate, sulfonate, xylenesulfonate, phenylacetate, phenpropionate, benzenebutanoic acid salt, citrate, lactate, γ-hydroxyl Base butyrate, oxyacetate, tartrate, methane sulfonates, propane sulfonic acid salt, naphthalene -1- sulfonate, naphthalene-2-sulfonic acid salt and almond Hydrochlorate.
Compound of the present invention as drug in use, be typically in the form of pharmaceutical composition be administered.Therefore, The pharmaceutical composition of compound and pharmaceutically acceptable carrier of the present invention, diluent or excipient is also included within this hair Bright range.Carrier used herein, auxiliary agent, excipient include being suitable for the arbitrary and all molten of desired particular dosage form Agent, diluent or other liquid excipients, dispersant or suspending agent, surfactant, isotonic agent, thickener or emulsifier are prevented Rotten agent, solid binder, lubricant etc..In Remington：The Science and Practice of Pharmacy, 21st Edition, 2005, ed.D.B.Troy, Lippincott Williams＆Wilkins, Philadelphia and Encyclopedia of Pharmaceutical Technology, eds.J.Swarbrick and J.C.Boylan, 1988- In 1999, Marcel Dekker, New York, various carriers and use for preparing pharmaceutically acceptable composition are disclosed In the known technology of its preparation, their content is all incorporated by reference herein.
Composition of the present invention can be administered by being suitable for any approach of illness to be treated.Particularly pass through with following Form is administered：It is parenteral, such as with Injectable solution or suspended form；It is enteral such as oral, such as with tablet or capsule Dosage form formula；Part, such as in the form of lotion, gel, ointment or emulsion or with nose or suppository form.Local application be for example using In skin.Another form of local administration is to deliver medicine to eye.
Pharmaceutical composition can be applied with solid, semisolid, liquid or gaseous form or can be in dry powder, such as Lyophilized form.Pharmaceutical composition can be packaged as the form convenient for transmitting, including such as solid dosage forms, such as capsule, anther sac, sachet Agent, gelatin, paper, tablet, suppository, granule, pill, lozenge and pastille.The type of packaging will generally depend on administration method.Also contain The preparation and percutaneous preparation of the implantable sustained release of lid.
It can include but not limited to as some examples of the material of pharmaceutically acceptable carrier：Ion-exchanger, oxidation Aluminium, aluminum stearate, lecithin, serum proteins (such as human serum albumins), buffer substance (such as phosphate), glycine, Sorbic acid or potassium sorbate, the partial glyceride mixture of saturated vegetable fatty acid, water, salt or electrolyte (such as sulfuric acid milt egg In vain, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt), colloidal silicon dioxide, magnesium trisilicate, polyvinylpyrrolidone, poly- third Olefin(e) acid ester, wax class, polyethylene-polyoxypropylene block copolymer, lanolin, carbohydrate (such as lactose, dextrose and saccharose), starch (such as cornstarch and potato starch), cellulose and its derivates, such as sodium carboxymethylcellulose, ethyl cellulose and vinegar Acid cellulose；Powdered tragacanth；Malt；Gelatin；Talcum powder；Excipient, such as cocoa butter and suppository wax；Oils, such as spend Oil generation, cottonseed oil；Safflower oil；Sesame oil；Olive oil；Corn oil and soybean oil；Glycol, such as propylene glycol or polyethylene glycol；Ester Class, such as ethyl oleate and ethyl laurate；Agar；Buffer, such as magnesium hydroxide and aluminium hydroxide；Alginic acid；Apyrogeneity Water；Isotonic saline solution；Ringer's solution；Ethyl alcohol；And phosphate buffer and other nontoxic compatible lubricants, such as the moon Osmanthus base sodium sulphate and magnesium stearate.According to the judgement of formulation scientist, there may also be colorant, releasing agent, packets in the composition Clothing agent, sweetener, flavoring agent and aromatic, preservative and antioxidant.
Compound of the present invention can be used alone or with other treatments disease of the present invention or illness (such as Cancer) therapeutic agent use.In certain embodiments, compound of the present invention is with having anti-hyperproliferation property Or second of compound for treatment height proliferative diseases (such as cancer) is combined or in medicine composition as connection Treatment is closed in dosage regimen to combine.The second compound of pharmaceutical combination preparations or Dosing schedules preferably has and this hair The activity of the bright compound complementation, so that they will not mutually have an adverse effect.Such compound is suitably by terms of Drawing purpose, effectively amount is present in combination.In one embodiment, the compound of the present invention and other antineoplastic Internet of Things It closes.The antitumor drug includes：Alkylating agents include but are not limited to cyclophosphamide, mustargen, melphalan, chlorambucil, card not Take charge of spit of fland；Metal platinum class includes but are not limited to carboplatin, cis-platinum, oxaliplatin；Topoisomerase enzyme inhibitor, including but not only limit In Topotecan, camptothecine, topotecan, Irinotecan；Antibiotics include but are not limited to fennel ciclamicin, D actinomycin D D, daunorubicin, adriamycin, mitoxantrone, bleomycin, plicamycin；Anti- micro-pipe or antimitotic agent, including but not only It is limited to taxol, vinorelbine, docetaxel, Doxorubicin；Antimetabolic species include but are not limited to fluorouracil, first ammonia Pterin, cytarabine, mercaptopurine (mecaptopurine), thioguanine and gemcitabine；Antibody class includes but are not limited to Trastuzumab, bevacizumab；Steroids, include but are not limited to Letrozole (Letrazole), R 83842 (vorazole), he not Western fragrant, Toremifene, fulvestrant, Flutamide, Nilutamide, Triptorelin；Kinase inhibitor class, EGFR kinase inhibitor, Include but are not limited to Gefitinib (gefitinib), Tarceva (erlotinib), Lapatinib (lapatinib), Ah Method replaces Buddhist nun (afatinib)；VEGFR inhibitor includes but are not limited to Sorafenib (Sorafenib), Rui Gefeini (Regorafenib), Sutent (Sunitinib), card it is rich for Buddhist nun (Cabozantinib), pazopanib (Pazopanib), Vande Thani (vandetanib), pazopanib (axitinib)；ALK inhibitor includes but are not limited to gram azoles for Buddhist nun (Crizotinib), Ceritinib (ceritinib), Alectinib；Bcr-Abl inhibitor includes but are not limited to her horse and replaces Buddhist nun (Imatinib), pa receive for Buddhist nun (Ponatinib), nilotinib (Nilotinib), Dasatinib (Dasatinib)；BTK Inhibitor includes but are not limited to replace Buddhist nun (Ibrutinib) according to Shandong；B-RAF inhibitor, includes but are not limited to Wei Luofeini (Vemurafenib)；Cell cycle protein dependent kinase CDK4/6 inhibitor, Pa Boxini (Palbociclib)；MTOR presses down Preparation includes but are not limited to rapamycin (rapamycin), everolimus (everolimus)；Deacetylase inhibitor, Include but are not limited to Vorinostat (vorinostat)；PD1/PDL1 antibody, Keytruda (Pembrolizumab), Opdivo(Nivolumab)。
Description of the drawings
Fig. 1 is tumor growth curve, which show embodiment 1 to human lung cancer NCI-H460 in nude mice by subcutaneous heteroplastic transplantation knurl Growth inhibition effect.
Specific embodiment
The following is specific embodiments of the present invention, and technical scheme of the present invention is further described, but this hair Bright protection domain is not limited to these embodiments.It is every to be included in without departing substantially from the change of present inventive concept or equivalent substitute In protection scope of the present invention.
In the examples below, annotated unless otherwise structural formula or chemical name, have the molecule at single chiral center with Racemic mixture form exists.It is annotated unless otherwise structural formula or chemical name, those have two or more chiralitys The molecule at center exists in the form of the racemic mixture of diastereoisomer.Single enantiomter/diastereoisomer can To be obtained by method known to those skilled in the art.
Preparation method
Compound of the present invention can be closed according to synthetic schemes herein and/or technology well known in the art Into.For example, compound provided by the invention can be prepared according to following universal synthesis method.
Specifically, in universal synthesis method, quinazoline compounds of the present invention can be reacted by 8 steps to be made It is standby.For example, starting material A is converted into compound B through bromo-reaction, compound C is obtained by the reaction with triphosgene.Compound C with Compound D is obtained by the reaction in N, O- dimethyl hydroxylamine hydrochloride, by methyl-magnesium-bromide attack generation compound E.Compound E and first Sour ammonium and formamide obtain the compound F with quinazoline skeleton, then removing methyl is reacted with alchlor, are led to With intermediate G.Intermediate G is reacted with various alcohol generation Mitsunobu or is reacted with various halides, obtains compound H. Under Suzuki reaction conditions well known by persons skilled in the art, compound F and compound H and the pyridine -3- boric acid of substitution are frequently Which alcohol ester is coupled to obtain compound 1-30.Alternatively, corresponding aryl boron is obtained by the reaction with connection pinacol borate in compound H Sour pinacol ester, then be coupled to obtain final product compound 1-30 with substituted 3- bromopyridines.
Universal synthesis method
Embodiment
Prepare embodiment
Compound of the present invention can be according to one or more synthetic schemes herein and/or skill well known in the art Art synthesizes.Those skilled in the art will appreciate that the synthetic method for the certain embodiments being described in detail in the present invention, can hold It is readily adapted for synthesis other embodiment.In some embodiments, compound as described herein can by it is well known that The appropriately combined of synthetic method prepare.Many starting materials and other reagents are purchased from commercial supplier, such as A Faai Sha (China) Chemical Co., Ltd. is easily prepared using synthetic method commonly used in the art.
1It is recorded on the instrument that H H NMR spectroscopies operate under 400MHz or 500MHz.H H NMR spectroscopies obtain in the form of a solution (with Ppm is reported), use CDCl3(7.26ppm) or DMSO-d6(2.50ppm) or internal standard tetramethylsilane (0.00ppm) are as reference Standard.When reporting peak multiplicity, following abbreviation is used：S (unimodal), d (bimodal), t (triplet), q (quartet), m is (multiple Peak), br (broad peak), dd (double doublet), dt (double triplets).The coupling Changshu provided is in terms of hertz (Hz).
When needing, (R)-and (S)-isomers of non-restrictive illustrative compound, if it does, this field can be passed through Method known to technical staff is split, such as by forming diastereomeric salt or compound, can for example, by crystallization and Separation；By forming diastereoisomerism derivative, can be detached for example, by crystallization or chromatography；Make an enantiomter With enantiomter specific reagent selective reaction, modified and unmodified enantiomter is then detached；Or Such as chromatographic isolation is carried out in the chiral environment of chiral chromatographic column.Alternatively, specific enantiomter can be by using Optical activity reagent, substrate, catalyst or solvent carry out asymmetric syntheses or by asymmetric transformation by an enantiomter Another is converted into prepare.
In following preparation method and example, " Me " refers to methyl, and " Ph " refers to phenyl, and " PE " refers to petroleum ether, " EtOAc " refers to ethyl acetate, and " MeOH " refers to methanol, and " EtOH " refers to ethyl alcohol, and " DMF " refers to n,N-Dimethylformamide, “CDCl3" refer to deuterochloroform, " DMSO-d6" refer to deuterated dimethyl sulfoxide, " DCM " refers to dichloromethane, and " DCE " refers to 1,2- Dichloroethanes, " THF " refer to tetrahydrofuran, and " HCl " refers to hydrochloric acid, and " TsOH " refers to p-methyl benzenesulfonic acid, " AlCl3" refer to trichlorine Change aluminium, " TEA " refers to triethylamine, and " NBS " refers to N- bromo-succinimides, " Na2SO4" refer to sodium sulphate, " K2CO3" refer to Potassium carbonate, " MeMgBr " refer to methyl-magnesium-bromide, and " DEAD " refers to diethyl azodiformate, " PPh3" refer to triphenylphosphine, “PdCl2(dppf) " refer to [1,1'- bis- (diphenylphosphino) ferrocene] palladium chloride, " Ar " refers to argon gas, and " M " refers to volume Molar concentration, " rt " refer to room temperature, and " min " refers to minute, and " h " refers to hour, and " mL " refers to milliliter, and " mmol " refers to mmoles You, " μM " refers to micromole, and " nM " refers to nanomole, and " DEG C " refers to degree Celsius.
The preparation of versatile intermediates (H)
Step 1：The preparation of the bromo- 3- methoxy benzoic acids (B) of 2- amino -5-
In 20min 2- amino -3- methoxy benzoic acids (A) are added to by NBS (28.04g, 157.5mmol) points 5 batches In the solution of (25.08g, 150mmol) in DMF (200mL).2h is stirred at room temperature in the reaction mixture of generation.Use water (2L) diluted reaction mixture, is extracted (500mL × 4) with EtOAc.Conjunction is washed with water (500mL × 3) and saline solution (500mL) And organic layer, use anhydrous Na2SO4Dry, filtering, being concentrated to give product crude product (B), (35g, yield are for dark brown solid 95%) it, is directly used in without further purification in next step.
1H NMR(400MHz,DMSO-d6) δ 7.42 (d, J=2.2Hz, 1H), 7.07 (d, J=2.2Hz, 1H), 3.84 (s, 3H)。
Step 2：[the preparation of -2,4 (1H)-diketone (C) of 1,3] oxazines of the bromo- 8- methoxyl groups -2H- benzos [d] of 6-
By compound (B) (35g, 142.2mmol) and triphosgene (32mg, 107.8mmol) in anhydrous THF (350mL) Mixture reflux 3h.After being cooled to room temperature, the solid of generation is collected by filtration, with PE/EtOAc solution (1:1, v/v, 200mL) Washing is dried to obtain product (C) as faint yellow solid (30.78g, yield 80%).
1H NMR(400MHz,DMSO-d6) δ 11.43 (s, 1H), 7.56 (d, J=2.0Hz, 1H), 7.55 (d, J= 2.0Hz,1H),3.92(s,3H)。
Step 3：The bromo- N of 2- amino -5-, the preparation of 3- Dimethoxy-N-methyls benzamide (D)
By compound (C) (30.78g, 113.12mmol), N, O- dimethyl hydroxylamine hydrochlorides (16.55g, 169.68mmol) it is refluxed overnight with mixtures of the TEA (26.7mL, 192.3mmol) in dioxane (300mL).Decompression is steamed Remove volatile matter.With water (500mL) diluted reaction mixture, extracted with EtOAc (200mL × 3).With water (200mL × 2) and salt The organic layer that water (200mL) washing merges, uses anhydrous Na2SO4It is dry, it filters, concentration.Residue through flash column chromatography (silica gel, PE/EtOAc=4:1, v/v) purifying obtains product (D) as yellow oil (29.73g, yield 91%).
1H NMR(400MHz,DMSO-d6) δ 7.01 (d, J=2.0Hz, 1H), 6.97 (d, J=2.0Hz, 1H), 5.10 (br s,2H),3.82(s,3H),3.53(s,3H),3.22(s,3H)。
Step 4：The preparation of 1- (the bromo- 3- methoxyphenyls of 2- amino -5-) ethyl ketone (E)
At -20 DEG C in argon gas atmosphere to compound (D) (29.73g, 103mmol) in anhydrous tetrahydro furan (300mL) Solution in, methyl-magnesium-bromide (1M tetrahydrofuran solutions, 206mL, 206mmol) is slowly added dropwise in 30min.By the anti-of generation Mixture is answered to stir 30min at -20 DEG C, is then quenched with saturated aqueous ammonium chloride.With water (1L) diluted reaction mixture, It is extracted with EtOAc (300mL × 3).The organic layer merged is washed with water (300mL × 2) and saline solution (300mL), use is anhydrous Na2SO4It is dry, it filters, concentration.Residue is through flash column chromatography (silica gel, PE/EtOAc=15:1, v/v) purifying obtains product (E) it is yellow oil (6.5g, yield 26%).
1H NMR(400MHz,DMSO-d6) δ 7.50 (d, J=2.0Hz, 1H), 7.08 (d, J=2.0Hz, 1H), 7.04 (s, 2H),3.84(s,3H),2.51(s,3H)。
Step 5：The preparation of the bromo- 8- methoxyl groups -4- methylquinazolins (F) of 6-
By compound (E) (3.328g, 13.63mmol) and ammonium formate (3.271g, 54.52mmol) in formamide (34mL) In reaction mixture stir 7h at 150 DEG C.Reaction mixture is cooled to room temperature, is diluted with water (150mL), with acetic acid second Ester extracts (100mL × 3).The organic layer merged is washed with water (100mL × 2) and saline solution (100mL), is done with anhydrous sodium sulfate It is dry, it filters, concentration.Residue is through flash column chromatography (silica gel, petrol ether/ethyl acetate=10:1 and then 4:1, v/v) it purifies It is yellow solid (2.492g, yield 72.2%) to product (F).
1H NMR(400MHz,DMSO-d6) δ 9.09 (s, 1H), 8.00 (d, J=1.9Hz, 1H), 7.54 (d, J=1.9Hz, 1H),4.00(s,3H),2.87(s,3H)。
Step 6：The preparation of the bromo- 4- methylquinazolins -8- phenol (G) of 6-
Tri-chlorination is added in into solution of the compound (F) (4.36g, 17.23mmol) in 1,2- dichloroethanes (390mL) Aluminium (6.90g, 51.69mmol).The reaction mixture of generation is stirred into 1.5h at 80 DEG C.Reaction mixture is cooled to room Temperature is diluted with water (400mL), is extracted (300mL × 2) with dichloromethane.Conjunction is washed with water (200mL) and saline solution (100mL) And organic layer, dried with anhydrous sodium sulfate, filter, concentration.Residue is through flash column chromatography (silica gel, DCM/MeOH=100: 1, v/v) purifying obtains product (G) as yellow solid (3.02g, yield 73.3%).
1H NMR(400MHz,DMSO-d6) δ 10.83 (s, 1H), 9.10 (s, 1H), 7.87 (d, J=2.0Hz, 1H), 7.41 (d, J=2.0Hz, 1H), 2.86 (s, 3H).
Embodiment 1：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (1)
Step 1：The preparation of the bromo- 4- methyl -8- of 6- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline (H-1)
At room temperature in argon gas atmosphere to the compound (G) (0.717g, 3mmol) that stirred, triphenylphosphine (0.944g, It adds in 3.6mmol) and in solution of the tetrahydrochysene -2H- pyrans -4- alcohol (0.368g, 3.6mmol) in anhydrous tetrahydro furan (30mL) DEAD (0.627g, 3.6mmol).The reaction mixture of generation is stirred at room temperature overnight.Silica gel (4g) is added in, by generation Evaporated under reduced pressure in mixture.Residue is through flash column chromatography (silica gel, DCM/EtOAc=4:1, v/v) purifying obtains product (H-1) For yellow solid (0.95g, yield 98%).
1H NMR(400MHz,DMSO-d6) δ 9.11 (s, 1H), 8.00 (d, J=2.0Hz, 1H), 7.71 (d, J=2.0Hz, 1H),5.03–4.88(m,1H),3.95–3.87(m,2H),3.58–3.49(m,2H),2.87(s,3H),2.10–2.01(m, 2H),1.78–1.61(m,2H)。
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline -6- bases) pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (1) preparation
By compound (H-1) (125mg, 0.39mmol), N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls -1,3,2- bis- Oxa- ring pentaborane -2- bases) pyridin-3-yl) -2,4- difluorobenzenesulfonamides (199mg, 0.47mmol) and 2M wet chemicals The mixture degassing of (0.585mL, 1.17mmol) in dioxane (7mL), then adds in PdCl2(dppf) (29mg, 0.04mmol).Reaction mixture degassing and backfilled with argon (three cycles) by generation, then at 100 DEG C in argon gas atmosphere Stir 5h.Reaction mixture is cooled to room temperature, is diluted with ethyl acetate (30mL) and water (30mL), being acidified to pH with hydrochloric acid is 5-6.Two-phase is detached, (30mL × 2) water layer is extracted with ethyl acetate.Having for merging is washed with water (50mL) and saline solution (50mL) Machine layer, is dried with anhydrous sodium sulfate, is filtered, concentration.Residue is through flash column chromatography (silica gel, DCM/MeOH=70:1 and then 50: 1, v/v) purifying obtains product (1) as yellow foamy solid (178mg, yield 85%).
1H NMR(400MHz,DMSO-d6) δ 10.35 (s, 1H), 9.08 (s, 1H), 8.56 (d, J=2.3Hz, 1H), 8.11 (d, J=2.3Hz, 1H), 7.94 (d, J=1.6Hz, 1H), 7.81-7.70 (m, 2H), 7.66-7.54 (m, 1H), 7.22 (dt, J =8.8,2.4Hz, 1H), 5.12-4.98 (m, 1H), 3.98-3.90 (m, 2H), 3.66 (s, 3H), 3.61-3.48 (m, 2H), 2.96(s,3H),2.16–2.03(m,2H),1.80–1.65(m,2H)。
MS(ESI+)m/z 543.1[M+H]+。
Embodiment 2：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) the chloro- 4- fluorobenzenesulfonamides (2) of -2-
According to the method for step 2 in embodiment 1, by compound (H-1) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) the chloro- 4- fluorobenzenesulfonamides prepare compounds (2) of -2-.
1H NMR(400MHz,DMSO-d6) δ 10.23 (s, 1H), 9.08 (s, 1H), 8.54 (d, J=2.3Hz, 1H), 8.05 (d, J=2.2Hz, 1H), 7.94 (dd, J=8.8,6.0Hz, 1H), 7.90 (d, J=1.6Hz, 1H), 7.77 (dd, J=8.8, 2.4Hz, 1H), 7.74 (d, J=1.6Hz, 1H), 7.37 (dt, J=8.4,2.4Hz, 1H), 5.11-5.00 (m, 1H), 3.97- 3.90(m,2H),3.67(s,3H),3.58–3.50(m,2H),2.95(s,3H),2.15–2.03(m,2H),1.81–1.66(m, 2H)。
MS(ESI+)m/z 559.1[M+H]+。
Embodiment 3：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) -5- chlorothiophene -2- sulfonamide (3)
According to the method for step 2 in embodiment 1, by compound (H-1) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -5- chlorothiophene -2- sulfonamide prepare compounds (3).
1H NMR(400MHz,DMSO-d6) δ 10.40 (s, 1H), 9.09 (s, 1H), 8.59 (d, J=2.2Hz, 1H), 8.10 (d, J=2.2Hz, 1H), 7.94 (d, J=1.4Hz, 1H), 7.77 (d, J=1.4Hz, 1H), 7.40 (d, J=4.0Hz, 1H), 7.25 (d, J=4.0Hz, 1H), 5.14-5.00 (m, 1H), 3.98-3.90 (m, 2H), 3.76 (s, 3H), 3.62-3.48 (m, 2H),2.96(s,3H),2.16–2.03(m,2H),1.82–1.66(m,2H)。
MS(ESI+)m/z 547.1[M+H]+。
Embodiment 4：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) Methanesulfomide (4)
According to the method for step 2 in embodiment 1, by compound (H-1) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) Methanesulfomide prepare compound (4).
1H NMR(400MHz,DMSO-d6) δ 9.42 (s, 1H), 9.08 (s, 1H), 8.55 (d, J=2.3Hz, 1H), 8.08 (d, J=2.3Hz, 1H), 7.96 (d, J=1.6Hz, 1H), 7.77 (d, J=1.6Hz, 1H), 5.13-4.99 (m, 1H), 4.00 (s,3H),3.97–3.90(m,2H),3.61–3.47(m,2H),3.10(s,3H),2.96(s,3H),2.14–2.01(m,2H), 1.82–1.66(m,2H)。
MS(ESI+)m/z 445.2[M+H]+。
Embodiment 5：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) cyclopropylsulfonamide (5)
According to the method for step 2 in embodiment 1, by compound (H-1) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) cyclopropylsulfonamide prepare compound (5).
1H NMR(400MHz,DMSO-d6) δ 9.48 (s, 1H), 9.08 (s, 1H), 8.56 (d, J=2.4Hz, 1H), 8.10 (d, J=2.4Hz, 1H), 7.96 (d, J=1.6Hz, 1H), 7.78 (d, J=1.6Hz, 1H), 5.12-5.02 (m, 1H), 4.01 (s,3H),3.99–3.90(m,2H),3.60–3.48(m,2H),2.96(s,3H),2.81–2.73(m,1H),2.16–2.03 (m,2H),1.81–1.66(m,2H),1.01–0.86(m,4H)。
MS(ESI+)m/z 471.2[M+H]+。
Embodiment 6：(R)-N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -3- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (6)
Step 1：(R) preparation of the bromo- 4- methyl -8- of -6- ((tetrahydrofuran -3- bases) oxygroup) quinazoline (H-6)
According to the method for step 1 in embodiment 1, by compound (G) and (S)-tetrahydrofuran -3- alcohol prepare compounds (H- 6)。
1H NMR(400MHz,DMSO-d6) δ 9.10 (s, 1H), 8.02 (d, J=1.9Hz, 1H), 7.55 (d, J=1.9Hz, 1H),5.37–5.31(m,1H),4.05–3.85(m,3H),3.83–3.76(m,1H),2.87(s,3H),2.39–2.25(m, 1H),2.14–2.01(m,1H)。
Step 2：(R)-N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -3- bases) oxygroup) quinazoline -6- bases) pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (6) preparation
According to the method for step 2 in embodiment 1, by compound (H-6) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (6).
1H NMR(400MHz,DMSO-d6) δ 10.35 (s, 1H), 9.08 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.12 (d, J=2.4Hz, 1H), 7.95 (d, J=1.6Hz, 1H), 7.76 (dt, J=8.6,6.4Hz, 1H), 7.65-7.54 (m, 2H), 7.22 (dt, J=8.6,2.4Hz, 1H), 5.51-5,45 (m, 1H), 4.05-3.90 (m, 3H), 3.86-3.78 (m, 1H), 3.66 (s,3H),2.96(s,3H),2.40–2.29(m,1H),2.21–2.08(m,1H)。
MS(ESI+)m/z 529.1[M+H]+。
Embodiment 7：(R)-N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -3- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) Methanesulfomide (7)
According to the method for step 2 in embodiment 1, by compound (H-6) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) Methanesulfomide prepare compound (7).
1H NMR(400MHz,DMSO-d6) δ 9.42 (s, 1H), 9.08 (s, 1H), 8.55 (d, J=2.4Hz, 1H), 8.09 (d, J=2.4Hz, 1H), 7.97 (d, J=1.6Hz, 1H), 7.63 (d, J=1.6Hz, 1H), 5.53-5.42 (m, 1H), 4.06- 3.90(m,6H),3.86–3.78(m,1H),3.11(s,3H),2.96(s,3H),2.41–2.28(m,1H),2.20–2.09(m, 1H)。
MS(ESI+)m/z 431.1[M+H]+。
Embodiment 8：(S)-N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -3- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (8)
Step 1：(S) preparation of the bromo- 4- methyl -8- of -6- ((tetrahydrofuran -3- bases) oxygroup) quinazoline (H-8)
According to the method for step 1 in embodiment 1, by compound (G) and (R)-tetrahydrofuran -3- alcohol prepare compounds (H- 8)。
1H NMR(400MHz,DMSO-d6) δ 9.10 (s, 1H), 8.02 (d, J=1.9Hz, 1H), 7.55 (d, J=1.9Hz, 1H),5.37–5.31(m,1H),4.05–3.85(m,3H),3.83–3.76(m,1H),2.87(s,3H),2.39–2.27(m, 1H),2.14–2.01(m,1H)。
Step 2：(S)-N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -3- bases) oxygroup) quinazoline -6- bases) pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (8) preparation
According to the method for step 2 in embodiment 1, by compound (H-8) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (8).
1H NMR(400MHz,DMSO-d6) δ 10.35 (s, 1H), 9.08 (s, 1H), 8.57 (d, J=2.2Hz, 1H), 8.12 (d, J=2.2Hz, 1H), 7.95 (d, J=1.2Hz, 1H), 7.77 (dt, J=8.8,6.6Hz, 1H), 7.66-7.55 (m, 2H), 7.22 (dt, J=8.8,2.4Hz, 1H), 5.52-5.43 (m, 1H), 4.06-3.89 (m, 3H), 3.86-3.78 (m, 1H), 3.66 (s,3H),2.96(s,3H),2.40–2.29(m,1H),2.20–2.08(m,1H)。
MS(ESI+)m/z 529.1[M+H]+。
Embodiment 9：(S)-N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -3- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) Methanesulfomide (9)
According to the method for step 2 in embodiment 1, by compound (H-8) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) Methanesulfomide prepare compound (9).
1H NMR(400MHz,DMSO-d6) δ 9.42 (s, 1H), 9.08 (s, 1H), 8.55 (d, J=2.3Hz, 1H), 8.09 (d, J=2.3Hz, 1H), 7.98 (d, J=1.6Hz, 1H), 7.63 (d, J=1.6Hz, 1H), 5.51-5.45 (m, 1H), 4.04- 3.9(m,6H),3.88–3.76(m,1H),3.11(s,3H),2.96(s,3H),2.42–2.26(m,1H),2.22–2.06(m, 1H)。
MS(ESI+)m/z 431.1[M+H]+。
Embodiment 10：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) methoxyl group) quinazoline -6- Base) pyridin-3-yl) -2,4 difluorobenzene sulfonamide (10)
Step 1：The preparation of the bromo- 4- methyl -8- of 6- ((tetrahydrochysene -2H- pyrans -4- bases) methoxyl group) quinazoline (H-10)
According to the method for step 1 in embodiment 1, chemical combination is prepared by compound (G) and (tetrahydrochysene -2H- pyrans -4- bases) methanol Object (H-10).
1H NMR(400MHz,DMSO-d6) δ 9.11 (s, 1H), 7.99 (d, J=1.9Hz, 1H), 7.56 (d, J=1.9Hz, 1H), 4.08 (d, J=6.5Hz, 2H), 3.94-3.87 (m, 2H), 3.38 (dt, J=11.8,2.0Hz, 2H), 2.87 (s, 3H), 2.21–2.08(m,1H),1.80–1.72(m,2H),1.48–1.34(m,2H)。
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) methoxyl group) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (10) preparation
According to the method for step 2 in embodiment 1, by compound (H-10) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (10).
1H NMR(400MHz,DMSO-d6) δ 10.34 (s, 1H), 9.08 (s, 1H), 8.58 (d, J=2.3Hz, 1H), 8.12 (d, J=2.3Hz, 1H), 7.92 (d, J=1.6Hz, 1H), 7.76 (dt, J=8.6,6.4Hz, 1H), 7.63 (d, J=1.6Hz, 1H), 7.62-7.55 (m, 1H), 7.22 (dt, J=8.4,2.2Hz, 1H), 4.17 (d, J=6.5Hz, 2H), 3.96-3.87 (m, 2H), 3.66 (s, 3H), 3.40 (dt, J=11.4,1.8Hz, 2H), 2.96 (s, 3H), 2.26-2.11 (m, 1H), 1.84-1.76 (m,2H),1.51–1.38(m,2H)。
MS(ESI+)m/z 557.2[M+H]+。
Embodiment 11：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) methoxyl group) quinazoline -6- Base) pyridin-3-yl) Methanesulfomide (11)
According to the method for step 2 in embodiment 1, by compound (H-10) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) Methanesulfomide prepare compound (11).
1H NMR(400MHz,DMSO-d6) δ 9.41 (s, 1H), 9.08 (s, 1H), 8.56 (d, J=2.4Hz, 1H), 8.09 (d, J=2.4Hz, 1H), 7.94 (d, J=1.6Hz, 1H), 7.65 (d, J=1.6Hz, 1H), 4.17 (d, J=6.5Hz, 2H), 4.01 (s, 3H), 3.96-3.88 (m, 2H), 3.39 (dt, J=11.7,1.9Hz, 2H), 3.10 (s, 3H), 2.95 (s, 3H), 2.25–2.11(m,1H),1.84–1.75(m,2H),1.51–1.37(m,2H)。
MS(ESI+)m/z 459.2[M+H]+。
Embodiment 12：N- (5- (8- (cyclohexyl oxygroup) -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) - 2,4 difluorobenzene sulfonamide (12)
Step 1：The preparation of the bromo- 8- of 6- (cyclohexyl oxygroup) -4- methylquinazolins (H-12)
According to the method for step 1 in embodiment 1, by compound (G) and cyclohexanol prepare compound (H-12).
1H NMR(400MHz,DMSO-d6) δ 9.09 (s, 1H), 7.97 (d, J=1.9Hz, 1H), 7.61 (d, J=1.9Hz, 1H),4.78–4.65(m,1H),2.86(s,3H),2.05–1.93(m,2H),1.82–1.72(m,2H),1.62–1.49(m, 3H),1.49–1.37(m,2H),1.37–1.25(m,1H)。
Step 2：N- (5- (8- (cyclohexyl oxygroup) -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) -2,4- The preparation of difluorobenzenesulfonamide (12)
According to the method for step 2 in embodiment 1, by compound (H-12) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (12).
1H NMR(400MHz,DMSO-d6) δ 10.35 (s, 1H), 9.07 (s, 1H), 8.55 (d, J=2.4Hz, 1H), 8.09 (d, J=2.4Hz, 1H), 7.90 (d, J=1.6Hz, 1H), 7.76 (dt, J=8.6,6.4Hz, 1H), 7.67 (d, J=1.6Hz, 1H),7.64–7.56(m,1H),7.26–7.19(m,1H),4.90–4.77(m,1H),3.67(s,3H),2.95(s,3H), 2.08–1.95(m,2H),1.87–1.73(m,2H),1.65–1.53(m,3H),1.52–1.27(m,3H)。
MS(ESI+)m/z 541.2[M+H]+。
Embodiment 13：N- (5- (8- (cyclopentyloxy) -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) - 2,4 difluorobenzene sulfonamide (13)
Step 1：The preparation of 6- bromo- 8- (cyclopentyloxy) -4- methylquinazolins (H-13)
According to the method for step 1 in embodiment 1, by compound (G) and cyclopentanol prepare compound (H-13).
1H NMR(400MHz,DMSO-d6) δ 9.09 (s, 1H), 7.96 (d, J=2.0Hz, 1H), 7.50 (d, J=2.0Hz, 1H),5.17–5.06(m,1H),2.86(s,3H),2.09–1.96(m,2H),1.88–1.72(m,4H),1.68–1.57(m, 2H)。
Step 2：N- (5- (8- (cyclopentyloxy) -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) -2,4- The preparation of difluorobenzenesulfonamide (13)
According to the method for step 2 in embodiment 1, by compound (H-13) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (13).
1H NMR(400MHz,DMSO-d6) δ 10.35 (s, 1H), 9.06 (s, 1H), 8.55 (d, J=2.4Hz, 1H), 8.08 (d, J=2.4Hz, 1H), 7.90 (d, J=1.6Hz, 1H), 7.77 (dt, J=8.6,6.4Hz, 1H), 7.64-7.57 (m, 1H), 7.57 (d, J=1.6Hz, 1H), 7.27-7.19 (m, 1H), 5.29-5.21 (m, 1H), 3.67 (s, 3H), 2.95 (s, 3H), 2.12–1.96(m,2H),1.94–1.73(m,4H),1.73–1.57(m,2H)。
MS(ESI+)m/z 527.2[M+H]+。
Embodiment 14：N- (5- (8- ((4,4- difiuorocyclohexyls) oxygroup) -4- methylquinazolin -6- bases) -2- methoxyl group pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (14)
Step 1：The preparation of the bromo- 8- of 6- ((4,4- difiuorocyclohexyls) oxygroup) -4- methylquinazolins (H-14)
According to the method for step 1 in embodiment 1, by compound (G) and 4,4- difluorocyclohex alcohol prepare compound (H-14).
1H NMR(400MHz,DMSO-d6) δ 9.12 (s, 1H), 8.03 (d, J=1.9Hz, 1H), 7.75 (d, J=1.9Hz, 1H),5.02–4.94(m,1H),2.87(s,3H),2.25–1.85(m,8H)。
Step 2：N- (5- (8- ((4,4- difiuorocyclohexyls) oxygroup) -4- methylquinazolin -6- bases) -2- methoxypyridines - 3- yls) -2,4 difluorobenzene sulfonamide (14) preparation
According to the method for step 2 in embodiment 1, by compound (H-14) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (14).
1H NMR(400MHz,DMSO-d6) δ 10.35 (s, 1H), 9.10 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.12 (d, J=2.4Hz, 1H), 7.97 (d, J=1.6Hz, 1H), 7.82 (d, J=1.6Hz, 1H), 7.76 (dt, J=8.6,6.4Hz, 1H), 7.64-7.55 (m, 1H), 7.22 (dt, J=8.4,2.2Hz, 1H), 5.15-5.05 (m, 1H), 3.66 (s, 3H), 2.96 (s,3H),2.31–2.11(m,2H),2.10–1.93(m,6H)。
MS(ESI+)m/z 577.2[M+H]+。
Embodiment 15：N- (5- (8- ((2,2- dimethyl tetrahydro -2H- pyrans -4- bases) oxygroup) -4- methylquinazolins -6- Base) -2- methoxypyridine -3- bases) -2,4 difluorobenzene sulfonamide (15)
Step 1：The bromo- 8- of 6- ((2,2- dimethyl tetrahydro -2H- pyrans -4- bases) oxygroup) -4- methylquinazolins (H-15) It prepares
According to the method for step 1 in embodiment 1, prepared by compound (G) and 2,2- dimethyl tetrahydro -2H- pyrans -4- alcohol Compound (H-15).
1H NMR(400MHz,DMSO-d6) δ 9.09 (s, 1H), 7.99 (d, J=1.8Hz, 1H), 7.72 (d, J=1.8Hz, 1H),5.12–4.97(m,1H),3.84–3.62(m,2H),2.86(s,3H),2.14–1.94(m,2H),1.64–1.45(m, 2H),1.25(s,3H),1.24(s,3H)。
Step 2：N- (5- (8- ((2,2- dimethyl tetrahydro -2H- pyrans -4- bases) oxygroup) -4- methylquinazolin -6- bases) - 2- methoxypyridine -3- bases) -2,4 difluorobenzene sulfonamide (15) preparation
According to the method for step 2 in embodiment 1, by compound (H-15) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (15).
1H NMR(400MHz,DMSO-d6) δ 10.35 (s, 1H), 9.07 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.12 (d, J=2.4Hz, 1H), 7.93 (d, J=1.6Hz, 1H), 7.81-7.71 (m, 2H), 7.64-7.56 (m, 1H), 7.26-7.19 (m,1H),5.24–5.09(m,1H),3.86–3.77(m,1H),3.75–3.67(m,1H),3.66(s,3H),2.96(s,3H), 2.14–2.01(m,2H),1.65–1.52(m,2H),1.26(s,3H),1.25(s,3H)。
MS(ESI+)m/z 571.2[M+H]+。
Embodiment 16：N- (2- methoxyl groups -5- (4- methyl -8- ((3- methy oxetane -3- bases) methoxyl group)-quinoline azoles Quinoline -6- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide (16)
Step 1：The preparation of the bromo- 4- methyl -8- of 6- ((3- methy oxetane -3- bases) methoxyl group) quinazoline (H-16)
According to the method for step 1 in embodiment 1, prepared by compound (G) and (3- methy oxetane -3- bases) methanol Compound (H-16).
1H NMR(400MHz,DMSO-d6) δ 9.13 (s, 1H), 8.02 (d, J=1.9Hz, 1H), 7.64 (d, J=1.9Hz, 1H), 4.57 (d, J=5.8Hz, 2H), 4.37 (d, J=5.8Hz, 2H), 4.32 (s, 2H), 2.88 (s, 3H), 1.45 (s, 3H).
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- ((3- methy oxetane -3- bases) methoxyl group)-quinazoline - 6- yls) pyridin-3-yl) -2,4 difluorobenzene sulfonamide (16) preparation
According to the method for step 2 in embodiment 1, by compound (H-16) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (16).
1H NMR(400MHz,DMSO-d6) δ 10.34 (s, 1H), 9.10 (s, 1H), 8.59 (d, J=2.4Hz, 1H), 8.14 (d, J=2.4Hz, 1H), 7.96 (d, J=1.6Hz, 1H), 7.80-7.74 (m, 1H), 7.73 (d, J=1.6Hz, 1H), 7.64- 7.56 (m, 1H), 7.22 (dt, J=8.4,2.4Hz, 1H), 4.61 (d, J=5.8Hz, 2H), 4.41 (s, 2H), 4.40 (d, J= 5.8Hz,2H),3.65(s,3H),2.97(s,3H),1.49(s,3H)。MS(ESI+)m/z 543.1[M+H]+。
Embodiment 17：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -2- bases) methoxyl group) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (17)
Step 1：The preparation of the bromo- 4- methyl -8- of 6- ((tetrahydrofuran -2- bases) methoxyl group) quinazoline (H-17)
According to the method for step 1 in embodiment 1, by compound (G) and tetrahydrofurfuryl alcohol prepare compound (H-17).
1H NMR(400MHz,DMSO-d6) δ 9.11 (s, 1H), 7.99 (d, J=1.8Hz, 1H), 7.57 (d, J=1.8Hz, 1H), 4.34-4.25 (m, 1H), 4.24-4.12 (m, 2H), 3.83 (dd, J=14.2,7.2Hz, 1H), 3.71 (dd, J= 14.2,7.2Hz,1H),2.87(s,3H),2.11–1.92(m,2H),1.90–1.70(m,2H)。
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -2- bases) methoxyl group) quinazoline -6- bases) pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (17) preparation
According to the method for step 2 in embodiment 1, by compound (H-17) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (17).
1H NMR(400MHz,DMSO-d6) δ 10.34 (s, 1H), 9.08 (s, 1H), 8.58 (d, J=2.2Hz, 1H), 8.13 (d, J=2.2Hz, 1H), 7.93 (d, J=1.2Hz, 1H), 7.76 (dt, J=8.4,6.4Hz, 1H), 7.65 (d, J=1.2Hz, 1H), 7.64-7.55 (m, 1H), 7.21 (dt, J=8.6,2.2Hz, 1H), 4.39-4.21 (m, 3H), 3.86 (dd, J=14.2, 7.0Hz, 1H), 3.73 (dd, J=14.2,7.0Hz, 1H), 3.65 (s, 3H), 2.96 (s, 3H), 2.14-1.93 (m, 2H), 1.93–1.73(m,2H)。
MS(ESI+)m/z 543.1[M+H]+。
Embodiment 18：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -3- bases) methoxyl group) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (18)
Step 1：The preparation of the bromo- 4- methyl -8- of 6- ((tetrahydrofuran -3- bases) methoxyl group) quinazoline (H-18)
According to the method for step 1 in embodiment 1, by compound (G) and (tetrahydrofuran -3- bases) methanol prepare compound (H-18)。
1H NMR(400MHz,DMSO-d6) δ 9.12 (s, 1H), 8.00 (d, J=1.8Hz, 1H), 7.59 (d, J=1.8Hz, 1H),4.21–4.08(m,2H),3.91–3.75(m,2H),3.74–3.59(m,2H),2.87(s,3H),2.84–2.75(m, 1H),2.11–2.02(m,1H),1.80–1.69(m,1H)。
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- ((tetrahydrofuran -3- bases) methoxyl group) quinazoline -6- bases) pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (18) preparation
According to the method for step 2 in embodiment 1, by compound (H-18) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (18).
1H NMR(400MHz,DMSO-d6) δ 10.34 (s, 1H), 9.09 (s, 1H), 8.58 (d, J=2.2Hz, 1H), 8.13 (d, J=2.2Hz, 1H), 7.94 (d, J=1.0Hz, 1H), 7.76 (dd, J=8.6,6.6Hz, 1H), 7.67 (d, J=1.0Hz, 1H), 7.65-7.53 (m, 1H), 7.22 (dt, J=8.6,2.4Hz, 1H), 4.35-4.16 (m, 2H), 3.93-3.78 (m, 2H), 3.75–3.60(m,5H),2.96(s,3H),2.92–2.76(m,1H),2.16–2.05(m,1H),1.83–1.73(m,1H)。
MS(ESI+)m/z 543.1[M+H]+。
Embodiment 19：N- (2- methoxyl groups -5- (4- methyl -8- ((1- methyl piperidine -4- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (19)
Step 1：The preparation of the bromo- 4- methyl -8- of 6- ((1- methyl piperidine -4- bases) oxygroup) quinazoline (H-19)
According to the method for step 1 in embodiment 1, by compound (G) and 1- methyl piperidine -4- alcohol prepare compounds (H- 19)。
1H NMR(400MHz,DMSO-d6) δ 9.10 (s, 1H), 7.99 (d, J=1.9Hz, 1H), 7.64 (d, J=1.9Hz, 1H),4.80–4.66(m,1H),2.88–2.85(m,3H),2.74–2.63(m,2H),2.30–2.14(m,6H),2.07–1.95 (m,2H),1.82–1.69(m,2H)。
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- ((1- methyl piperidine -4- bases) oxygroup) quinazoline -6- bases) pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (19) preparation
According to the method for step 2 in embodiment 1, by compound (H-19) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (19).
1H NMR(400MHz,DMSO-d6) δ 9.07 (s, 1H), 8.35 (d, J=2.2Hz, 1H), 7.93 (d, J=2.2Hz, 1H), 7.86 (d, J=1.6Hz, 1H), 7.79 (dt, J=8.6,6.6Hz, 1H), 7.66 (d, J=1.6Hz, 1H), 7.54- 7.44 (m, 1H), 7.18 (dt, J=8.4,2.4Hz, 1H), 4.95-4.82 (m, 1H), 3.70 (s, 3H), 2.94 (s, 3H), 2.93–2.86(m,2H),2.51(s,1H),2.39(s,3H),2.15–2.04(m,2H),1.92–1.80(m,2H)。
MS(ESI+)m/z 556.2[M+H]+。
Embodiment 20：N- (2- methoxyl groups -5- (4- methyl -8- (2- (pyrrolidin-1-yl) ethyoxyl) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (20)
Step 1：The preparation of the bromo- 4- methyl -8- of 6- (2- (pyrrolidin-1-yl) ethyoxyl) quinazoline (H-20)
According to the method for step 1 in embodiment 1, chemical combination is prepared by compound (G) and 2- (pyrrolidin-1-yl) second -1- alcohol Object (H-20).
1H NMR(400MHz,DMSO-d6) δ 9.10 (s, 1H), 7.99 (d, J=1.9Hz, 1H), 7.58 (d, J=1.9Hz, 1H), 4.30 (t, J=5.8Hz, 2H), 2.93 (t, J=5.8Hz, 2H), 2.87 (s, 3H), 2.64-2.55 (m, 4H), 1.76- 1.62(m,4H)。
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- (2- (pyrrolidin-1-yl) ethyoxyl) quinazoline -6- bases) pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (20) preparation
According to the method for step 2 in embodiment 1, by compound (H-20) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (20).
1H NMR(400MHz,DMSO-d6) δ 9.08 (s, 1H), 8.37 (d, J=2.2Hz, 1H), 7.96 (d, J=2.2Hz, 1H), 7.86 (d, J=1.4Hz, 1H), 7.80 (dt, J=8.6,6.6Hz, 1H), 7.61 (d, J=1.4Hz, 1H), 7.53- 7.45 (m, 1H), 7.19 (dt, J=8.4,2.4Hz, 1H), 4.45 (t, J=5.5Hz, 2H), 3.69 (s, 3H), 3.18 (t, J= 5.5Hz,2H),2.95(s,3H),2.91–2.81(m,4H),1.83–1.75(m,4H)。
MS(ESI+)m/z 556.2[M+H]+。
Embodiment 21：N- (5- (8- (2- (1H- pyrazol-1-yls) ethyoxyl) -4- methylquinazolin -6- bases) -2- methoxyl groups Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (21)
Step 1：The preparation of 8- (2- (1H- pyrazol-1-yls) ethyoxyl) bromo- 4- methylquinazolins (H-21) of -6-
According to the method for step 1 in embodiment 1, chemical combination is prepared by compound (G) and 2- (1H- pyrazol-1-yls) second -1- alcohol Object (H-21).
1H NMR(400MHz,DMSO-d6) δ 9.11 (s, 1H), 8.01 (d, J=1.9Hz, 1H), 7.87 (dd, J=2.2, 0.6Hz, 1H), 7.54 (d, J=1.9Hz, 1H), 7.46 (dd, J=1.8,0.6Hz, 1H), 6.24 (t, J=2.0Hz, 1H), 4.65–4.57(m,4H),2.86(s,3H)。
Step 2：N- (5- (8- (2- (1H- pyrazol-1-yls) ethyoxyl) -4- methylquinazolin -6- bases) -2- methoxyl group pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (21) preparation
According to the method for step 2 in embodiment 1, by compound (H-21) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (21).
1H NMR(400MHz,DMSO-d6) δ 10.33 (s, 1H), 9.09 (s, 1H), 8.56 (d, J=2.3Hz, 1H), 8.12 (d, J=2.3Hz, 1H), 7.95 (d, J=1.6Hz, 1H), 7.92 (dd, J=2.2,0.6Hz, 1H), 7.76 (dt, J=8.4, 6.4Hz, 1H), 7.62 (d, J=1.6Hz, 1H), 7.61-7.56 (m, 1H), 7.46 (dd, J=1.8,0.6Hz, 1H), 7.22 (dt, J=8.4,2.0Hz, 1H), 6.27-6.23 (m, 1H), 4.76-4.60 (m, 4H), 3.65 (s, 3H), 2.95 (s, 3H).
MS(ESI+)m/z 553.1[M+H]+。
Embodiment 22：N- (2- methoxyl groups -5- (4- methyl -8- (2- morpholines base oxethyl) quinazoline -6- bases) pyridine -3- Base) -2,4 difluorobenzene sulfonamide (22)
Step 1：The preparation of 4- (2- ((the bromo- 4- methylquinazolins -8- bases of 6-) oxygroup) ethyl) morpholine (H-22)
According to the method for step 1 in embodiment 1, by compound (A-8) and 2- morpholinyl second -1- alcohol prepare compounds (H- 22)。
1H NMR(400MHz,DMSO-d6) δ 9.10 (s, 1H), 7.99 (d, J=1.9Hz, 1H), 7.61 (d, J=1.9Hz, 1H), 4.33 (t, J=5.7Hz, 2H), 3.63-3.53 (m, 4H), 2.87 (s, 3H), 2.82 (t, J=5.7Hz, 2H), 2.59- 2.51(m,4H)。
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- (2- morpholines base oxethyl) quinazoline -6- bases) pyridin-3-yl) - The preparation of 2,4 difluorobenzene sulfonamide (22)
According to the method for step 2 in embodiment 1, by compound (H-22) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (22).
1H NMR(400MHz,DMSO-d6) δ 10.33 (s, 1H), 9.08 (s, 1H), 8.57 (d, J=2.4Hz, 1H), 8.12 (d, J=2.4Hz, 1H), 7.93 (d, J=1.6Hz, 1H), 7.76 (dt, J=8.6,6.4Hz, 1H), 7.67 (d, J=1.6Hz, 1H), 7.59 (ddd, J=10.6,9.2,2.4Hz, 1H), 7.27-7.18 (m, 1H), 4.43 (t, J=5.6Hz, 2H), 3.66 (s, 3H), 3.64-3.57 (m, 4H), 2.96 (s, 3H), 2.89 (t, J=5.6Hz, 2H), 2.65-2.56 (m, 4H).
MS(ESI+)m/z 571.2[M+H]+。
Embodiment 23：N- (2- methoxyl groups -5- (4- methyl -8- ((1- methyl piperidine -4- bases) methoxyl group) quinazoline -6- Base) pyridin-3-yl) -2,4 difluorobenzene sulfonamide (23)
Step 1：The preparation of the bromo- 4- methyl -8- of 6- ((1- methyl piperidine -4- bases) methoxyl group) quinazoline (H-23)
According to the method for step 1 in embodiment 1, by compound (G) and (1- methyl piperidine -4- bases) methanol prepare compound (H-23)。
1H NMR(400MHz,DMSO-d6) δ 9.11 (s, 1H), 7.98 (d, J=1.8Hz, 1H), 7.54 (d, J=1.8Hz, 1H), 4.06 (d, J=6.0Hz, 2H), 2.86 (s, 3H), 2.84-2.76 (m, 1H), 2.17 (s, 3H), 1.95-1.75 (m, 5H),1.44–1.31(m,2H)。
Step 2：N- (2- methoxyl groups -5- (4- methyl -8- ((1- methyl piperidine -4- bases) methoxyl group) quinazoline -6- bases) pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (23) preparation
According to the method for step 2 in embodiment 1, by compound (H-23) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (23).
1H NMR(400MHz,DMSO-d6) δ 9.06 (s, 1H), 8.25 (d, J=1.6Hz, 1H), 7.86-7.80 (m, 2H), 7.78 (d, J=1.4Hz, 1H), 7.51 (d, J=1.4Hz, 1H), 7.43 (dt, J=9.8,2.4Hz, 1H), 7.16 (dt, J= 8.4,2.4Hz, 1H), 4.15 (d, J=6.0Hz, 2H), 3.72 (s, 3H), 3.16-3.07 (m, 2H), 2.93 (s, 3H), 2.48- 2.34(m,5H),2.08–1.87(m,3H),1.61–1.41(m,2H)。
MS(ESI+)m/z 570.2[M+H]+。
Embodiment 24：N- (5- (8- (2- (dimethylamino) ethyoxyl) -4- methylquinazolin -6- bases) -2- methoxyl group pyrroles Pyridine -3- bases) -2,4 difluorobenzene sulfonamide (24)
Step 1：2- ((the bromo- 4- methylquinazolins -8- bases of 6-) methoxyl group)-N, N- dimethyl ethanol -1- amine (H-24) It prepares
According to the method for step 1 in embodiment 1, by compound (G) and 2- (dimethylamino) second -1- alcohol prepare compounds (H-24)。
1H NMR(400MHz,DMSO-d6) δ 9.11 (s, 1H), 8.03 (d, J=1.9Hz, 1H), 7.63 (d, J=1.9Hz, 1H), 4.40 (t, J=5.2Hz, 2H), 3.03 (t, J=5.2Hz, 2H), 2.88 (s, 3H), 2.48 (s, 6H).
Step 2：N- (5- (8- (2- (dimethylamino) ethyoxyl) -4- methylquinazolin -6- bases) -2- methoxypyridines -3- Base) -2,4 difluorobenzene sulfonamide (24) preparation
According to the method for step 2 in embodiment 1, by compound (H-24) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (24).
1H NMR(400MHz,DMSO-d6) δ 9.08 (s, 1H), 8.44 (d, J=2.3Hz, 1H), 8.01 (d, J=2.3Hz, 1H), 7.89 (d, J=1.6Hz, 1H), 7.79 (dt, J=8.6,6.4Hz, 1H), 7.64 (d, J=1.6Hz, 1H), 7.56- 7.48 (m, 1H), 7.24-7.16 (m, 1H), 4.43 (t, J=5.6Hz, 2H), 3.68 (s, 3H), 2.98 (t, J=5.6Hz, 2H),2.95(s,3H),2.44(s,6H)。
MS(ESI+)m/z 530.2[M+H]+。
Embodiment 25：N- (5- (8- (cyclo propyl methoxy) -4- methylquinazolin -6- bases) -2- methoxypyridines -3- Base) -2,4 difluorobenzene sulfonamide (25)
Step 1：The preparation of 6- bromo- 8- (cyclo propyl methoxy) -4- methylquinazolins (H-25)
To the compound (G) (0.120g, 0.5mmol) that stirred in seal pipe, the third methyl bromide of ring (0.675g, 5mmol) it is stirred overnight at 85 DEG C with mixture of the potassium carbonate (0.691g, 5mmol) in acetonitrile (8mL).By the mixed of generation It closes object to be cooled to room temperature, then filter.Silica gel (1g) is added in into filtrate, by the mixture evaporated under reduced pressure of generation.Residue passes through Flash column chromatography (silica gel, DCM/MeOH=150:1, v/v) purifying obtains product (H-25) as yellow oil (0.142g, production 97%) rate is.
1H NMR(400MHz,DMSO-d6) δ 9.11 (s, 1H), 7.97 (d, J=2.0Hz, 1H), 7.49 (d, J=2.0Hz, 1H), 4.05 (d, J=7.1Hz, 2H), 2.87 (s, 3H), 1.41-1.29 (m, 1H), 0.68-0.57 (m, 2H), 0.43-0.36 (m,2H)。
Step 2：N- (5- (8- (cyclo propyl methoxy) -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) -2, The preparation of 4- difluorobenzenesulfonamides (25)
According to the method for step 2 in embodiment 1, by compound (H-25) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (25).
1H NMR(400MHz,DMSO-d6) δ 10.33 (s, 1H), 9.08 (s, 1H), 8.55 (d, J=2.2Hz, 1H), 8.09 (d, J=2.2Hz, 1H), 7.91 (d, J=1.4Hz, 1H), 7.76 (dt, J=8.6,6.4Hz, 1H), 7.63-7.57 (m, 1H), 7.57 (d, J=1.4Hz, 1H), 7.21 (dt, J=8.4,2.4Hz, 1H), 4.15 (d, J=7.0Hz, 2H), 3.65 (s, 3H), 2.96(s,3H),1.47–1.32(m,1H),0.71–0.60(m,2H),0.46–0.37(m,2H)。
MS(ESI+)m/z 513.1[M+H]+。
Embodiment 26：N- (5- (8- isopropoxy base -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) -2, 4- difluorobenzenesulfonamides (26)
Step 1：The preparation of the bromo- 8- isopropoxies -4- methylquinazolins (H-26) of 6-
According to the method for step 1 in embodiment 25, by compound (G) and isopropyl bromide prepare compound (H-26).
1H NMR(400MHz,DMSO-d6) δ 9.08 (s, 1H), 7.97 (d, J=2.0Hz, 1H), 7.57 (d, J=2.0Hz, 1H), 5.00-4.89 (m, 1H), 2.86 (s, 3H), 1.37 (d, J=6.0Hz, 6H).
Step 2：N- (5- (8- isopropoxy -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) -2,4- difluoros The preparation of benzsulfamide (26)
According to the method for step 2 in embodiment 1, by compound (H-26) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepares title compound (26).
1H NMR(400MHz,DMSO-d6) δ 10.34 (s, 1H), 9.06 (s, 1H), 8.55 (d, J=2.3Hz, 1H), 8.08 (d, J=2.3Hz, 1H), 7.91 (d, J=1.6Hz, 1H), 7.77 (dt, J=8.6,6.4Hz, 1H), 7.63 (d, J=1.6Hz, 1H), 7.62-7.55 (m, 1H), 7.22 (dt, J=8.4,2.2Hz, 1H), 5.13-5.02 (m, 1H), 3.67 (s, 3H), 2.95 (s, 3H), 1.40 (d, J=6.0Hz, 6H).
MS(ESI+)m/z 501.1[M+H]+。
Embodiment 27：N- (5- (8- cyclobutoxy group -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) -2,4- Difluorobenzenesulfonamide (27)
Step 1：The preparation of the bromo- 8- cyclobutoxy groups -4- methylquinazolins (H-27) of 6-
According to the method for step 1 in embodiment 25, by compound (G) and cyclobutyl bromine prepare compound (H-27).
1H NMR(400MHz,DMSO-d6) δ 9.10 (s, 1H), 7.99 (d, J=1.9Hz, 1H), 7.33 (d, J=1.9Hz, 1H), 4.97 (p, J=7.2Hz, 1H), 2.86 (s, 3H), 2.59-2.52 (m, 2H), 2.23-2.08 (m, 2H), 1.91-1.80 (m,1H),1.79–1.61(m,1H)。
Step 2：N- (5- (8- cyclobutoxy group -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) -2,4- difluoros The preparation of benzsulfamide (27)
According to the method for step 2 in embodiment 1, by compound (H-27) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (27).
1H NMR(400MHz,DMSO-d6) δ 10.36 (s, 1H), 9.07 (s, 1H), 8.54 (d, J=2.2Hz, 1H), 8.07 (d, J=2.2Hz, 1H), 7.92 (s, 1H), 7.76 (dt, J=8.4,6.4Hz, 1H), 7.64-7.56 (m, 1H), 7.40 (s, 1H), 7.23 (dt, J=8.4,2.4Hz, 1H), 5.16-5.02 (m, 1H), 3.68 (s, 3H), 2.95 (s, 3H), 2.62-2.52 (m,2H),2.29–2.10(m,2H),1.94–1.81(m,1H),1.80–1.65(m,1H)。
MS(ESI+)m/z 513.1[M+H]+。
Embodiment 28：N- (5- (8- (difluoro-methoxy) -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) - 2,4 difluorobenzene sulfonamide (28)
Step 1：The preparation of 6- bromo- 8- (difluoro-methoxy) -4- methylquinazolins (H-28)
To the compound (G) (0.120g, 0.5mmol) that stirred in seal pipe, chlorine methyl difluoroacetate (0.217g, 1.5mmol) and mixture of the sodium carbonate (0.159g, 1.5mmol) in dimethylformamide (3mL) stirs 8h at 70 DEG C. The mixture of generation is cooled to room temperature, is diluted, is extracted with ethyl acetate (30mL × 3) with water (30mL).With water (30mL) and The organic layer that saline solution (30mL) washing merges, is dried with anhydrous sodium sulfate, is filtered, concentration.Residue is through preparing thin-layer chromatography (silica gel, DCM/MeOH=40:1, v/v) purifying obtains product (H-28) as yellow oil (0.080g, yield 55%).
1H NMR(400MHz,DMSO-d6) δ 9.21 (s, 1H), 8.43 (d, J=2.0Hz, 1H), 7.98 (d, J=2.0Hz, 1H), 7.53 (t, J=73.8Hz, 1H), 2.94 (s, 3H).
Step 2：N- (5- (8- (difluoro-methoxy) -4- methylquinazolin -6- bases) -2- methoxypyridine -3- bases) -2,4- The preparation of difluorobenzenesulfonamide (28)
According to the method for step 2 in embodiment 1, by compound (H-28) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls Base -1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (28).
1H NMR(400MHz,DMSO-d6) δ 10.37 (s, 1H), 9.18 (s, 1H), 8.59 (d, J=2.4Hz, 1H), 8.35 (d, J=1.8Hz, 1H), 8.16 (d, J=2.4Hz, 1H), 8.06 (d, J=1.8Hz, 1H), 7.76 (dt, J=8.6,6.4Hz, 1H), 7.64-7.55 (m, 1H), 7.56 (t, J=74.0Hz, 1H), 7.21 (dt, J=8.4,2.0Hz, 1H), 3.66 (s, 3H), 3.03(s,3H)。
Embodiment 29：N- (2- methoxyl groups -5- (8- methoxyl group -4- methylquinazolin -6- bases) pyridin-3-yl) -2,4- two Fluorobenzenesulfonamide (29)
According to the method for step 2 in embodiment 1, by compound (F) and N- (2- methoxyl groups -5- (4,4,5,5- tetramethyls - 1,3,2- dioxaborolanes -2- bases) pyridin-3-yl) -2,4 difluorobenzene sulfonamide prepare compound (29).
1H NMR(400MHz,DMSO-d6) δ 10.35 (s, 1H), 9.06 (s, 1H), 8.58 (d, J=2.2Hz, 1H), 8.13 (d, J=2.2Hz, 1H), 7.93 (d, J=1.6Hz, 1H), 7.77 (dt, J=8.4,6.4Hz, 1H), 7.65-7.54 (m, 2H), 7.23 (dt, J=8.6,2.4Hz, 1H), 4.08 (s, 3H), 3.67 (s, 3H), 2.96 (s, 3H).
MS(ESI+)m/z 473.1[M+H]+。
Embodiment 30：N- (the chloro- 5- of 2- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline -6- bases) pyrroles Pyridine -3- bases) -4- fluorobenzenesulfonamides (30)
By compound (H-1) (71mg, 0.22mmol), acetic anhydride potassium (65mg, 0.66mmol) and connection boric acid pinacol Mixture degassing of the ester (64mg, 0.25mmol) in dioxane (8mL), then adds in PdCl2(dppf) (16mg, 0.022mmol).Reaction mixture degassing and backfilled with argon (three cycles) by generation, are stirred at 100 DEG C in argon gas atmosphere 4h.After being cooled to room temperature, into the mixture of generation add in N- (the bromo- 2- chloropyridines -3- bases of 5-) -4- fluorobenzenesulfonamides (91mg, 0.25mmol) and 2M wet chemicals (0.44mL, 0.88mmol).The mixture of generation is deaerated, then adds in PdCl2 (dppf) (16mg, 0.022mmol).Reaction mixture degassing and backfilled with argon (three cycles) by generation, then at 100 DEG C 5h is stirred in lower argon gas atmosphere.Reaction mixture is cooled to room temperature, is diluted with ethyl acetate (30mL) and water (30mL), uses salt Acid is acidified to pH as 5-6.Two-phase is detached, (30mL × 2) water layer is extracted with ethyl acetate.With water (50mL) and saline solution (50mL) The organic layer merged is washed, is dried with anhydrous sodium sulfate, is filtered, concentration.Residue prepares chromatography (DCM/MeOH=through thin layer 15:1, v/v) purifying obtains product (30) as yellow foamy solid (42mg, yield 35%).
1H NMR(400MHz,DMSO-d6) δ 10.57 (s, 1H), 9.12 (s, 1H), 8.79 (d, J=2.2Hz, 1H), 8.16 (d, J=2.2Hz, 1H), 8.00 (d, J=1.6Hz, 1H), 7.87-7.80 (m, 2H), 7.78 (d, J=1.6Hz, 1H), 7.50- 7.39(m,2H),5.12–5.00(m,1H),3.98–3.90(m,2H),3.60–3.50(m,2H),2.97(s,3H),2.15– 2.02(m,2H),1.82–1.65(m,2H)。
MS(ESI+)m/z 529.1[M+H]+。
Embodiment 31：N- (2- methyl -5- (4- methyl -8- ((tetrahydrochysene -2H- pyrans -4- bases) oxygroup) quinazoline -6- bases) Pyridin-3-yl) -2,4 difluorobenzene sulfonamide (31)
By compound (H-1) (71mg, 0.22mmol), acetic anhydride potassium (65mg, 0.66mmol) and connection boric acid pinacol Mixture degassing of the ester (64mg, 0.25mmol) in dioxane (8mL), then adds in PdCl2(dppf) (16mg, 0.022mmol).Reaction mixture degassing and backfilled with argon (three cycles) by generation, are stirred at 100 DEG C in argon gas atmosphere 4h.After being cooled to room temperature, N- (5- bromine-2-methylpyridine -3- bases) -2,4- difluorobenzenesulfonamides are added in into the mixture of generation (91mg, 0.25mmol) and 2M wet chemicals (0.44mL, 0.88mmol).The mixture of generation is deaerated, is then added in PdCl2(dppf) (16mg, 0.022mmol).Reaction mixture degassing and backfilled with argon (three cycles) by generation, Ran Hou At 100 DEG C 5h is stirred in argon gas atmosphere.Reaction mixture is cooled to room temperature, it is dilute with ethyl acetate (30mL) and water (30mL) It releases, it is 5-6 to be acidified to pH with hydrochloric acid.Two-phase is detached, (30mL × 2) water layer is extracted with ethyl acetate.With water (50mL) and salt The organic layer that water (50mL) washing merges, is dried with anhydrous sodium sulfate, is filtered, concentration.Residue prepares chromatography (DCM/ through thin layer MeOH=15:1, v/v) purifying obtains product (31) as yellow foamy solid (46mg, yield 40%).
1H NMR(400MHz,DMSO-d6) δ 10.53 (s, 1H), 9.10 (s, 1H), 8.84 (s, 1H), 7.88 (d, J= 1.6Hz, 1H), 7.85 (d, J=2.0Hz, 1H), 7.80 (dt, J=8.6,6.4Hz, 1H), 7.71 (d, J=1.6Hz, 1H), 7.67–7.59(m,1H),7.30–7.24(m,1H),5.08–4.99(m,1H),3.97–3.90(m,2H),3.58–3.50(m, 2H),2.94(s,3H),2.34(s,3H),2.16–2.01(m,2H),1.82–1.64(m,2H)。
MS(ESI+)m/z 527.2[M+H]+。
Pharmacological activity is evaluated
Embodiment 32：Biochemistry detects PI3K alpha actives
Using vitro kinase check and evaluation the compound of the present invention to the efficiency of PI3K α.Using based on the cold of luciferase Light detection measures the kinase activity of PI3K- α by detecting in kinase reaction generated ADP levels.Kinase-GloTMSwash Enzyme detection kit is purchased from Promega companies.All detections carry out at room temperature, use OptiPlateTM- 384 whites 384 Orifice plate.PI3K alpha kinases come from Invitrogen.Substrate is PIP2 (Invitrogen).Kinase buffer liquid includes 50mM Hepes (pH 7.5), 3mM MgCl2, 100mM NaCl, 1mM EGTA, 0.03%CHAPS and 2mM DTT.By in kinase buffer liquid PI3K alpha kinases are diluted to 6.6nM and prepare PI3K alpha kinase solution.Substrate solution includes 100 μM of PIP2 and 50 μM of ATP.It will treat It surveys compound and 10mM is diluted in 100%DMSO, 3 times of serial dilutions are then pressed in 100%DMSO into 10 various concentrations. Then the compound being diluted in 100%DMSO is diluted 25 times in 1 × kinase buffer liquid.By the 2.5 diluted compounds of μ L The PI3K alpha kinase solution of solution and 2.5 μ L are added in each hole of 384 orifice plates.Started instead by the substrate solution added in per 5 μ L of hole Should, end reaction volume be a concentration of 25 μM of 10 μ L, ATP, a concentration of 50 μM of PIP2, a concentration of 1.65nM of PI3K alpha kinases.By plate It covers and carries out reaction 1 hour in room temperature, then add in the kinases Kinase-Glo per 10 μ L of holeTMReagent terminates reaction.It will Plate is incubated 15 minutes, then reads cold light in 2104 multiple labeling micropore board detector plate reader of EnVision.
Percentage is inhibited to be calculated based on the following formula：
Inhibit %=100- (max-sample RLU)/(max-min) * 100.
Wherein sample RLU are the cold light reading under given compound concentration, and min refers to the reading of DMSO controls, max Refer to the reading of no enzyme activity control.The IC of compound is calculated by using in XLfit programs in Excel50, the results are shown in Table 1.
Table 1：PI3K alpha kinase inhibitory activity
Embodiment 33：Mtt assay measures the survival rate of tumour cell
After the human lung carcinoma cell NCI-H460 of exponential phase is digested with 0.25% pancreas enzyme -EDTA, it is configured to certain dense The single cell suspension of degree is inoculated in 96 orifice plates by 1200/hole, per hole add in 100 μ L, for 24 hours after, add in the to be measured of various concentration Compound and the fresh culture of coordinative solvent control, add 100 μ L (DMSO final concentrations per hole<0.2%), each test-compound If 6-9 concentration group, every group sets three parallel holes.In 5%CO2, continue to cultivate 96h at 37 DEG C, add in that 20 μ L are fresh to be matched per hole The PBS solution of the MTT containing 5mg/mL of system, continues after cultivating 4h, abandons supernatant, and it is heavy that 150 μ L DMSO dissolving MTT first hairpins are added in per hole It forms sediment, after microoscillator shakes mixing, OD value (optical density, OD) is measured under the conditions of wavelength 570nm, And the tumour cell handled using DMSO solvents calculates suppression of the untested compound to growth of tumour cell as control group with following equation Rate processed, and pass through SPSS16.0 and calculate IC50：
Inhibiting rate (%)=(ODControl- ODCompound)/ODControl× 100%
Wherein, ODControlFor the mean OD value of control group, ODControlTo give the mean OD value under compound concentration.
It the results are shown in Table 2.
Table 2：To the antiproliferative activity of human lung carcinoma cell NCI-H460
Embodiment 35：Nude mouse xenograft efficacy study
Human lung cancer NCI-H460 tumour cells are collected under aseptic condition, with sterile saline adjust cell density to 1 × 106A/ml takes 0.2ml to be inoculated in nude mice armpit dorsal sc, treats tumour growth to diameter 1cm sizes, is taken out under aseptic condition, The tumor mass of 1mm × 1mm sizes is cut into, is uniformly inoculated in nude mice armpit dorsal sc.Treat tumour growth to 100~300mm after 6 days3 Afterwards, animal is grouped at random, starts that (being denoted as the 1st day) is administered.Untested compound is administered orally daily.It weighs in twice a week And with the length and width of vernier caliper measurement tumour, nude mice after 16 days is dislocated and put to death by administration, is removed tumor tissues, is weighed simultaneously It takes pictures.Tumor control rate is finally calculated, antitumor action intensity is evaluated with tumor control rate, the results are shown in Table 3 and Fig. 1.
Gross tumor volume is calculated according to the following formula：
Gross tumor volume=(a × b2)/2, a and b represents knurl length and width respectively.
Tumor growth inhibition percentage is calculated according to the following formula：
Tumor growth inhibition (%)=(1-T/C) × 100, T is the final gross tumor volume of untested compound group, and C is solvent pair According to the final gross tumor volume of group.
3. embodiment 1 of table to human lung cancer NCI-H460 nude mice by subcutaneous heteroplastic transplantation knurl growth inhibition
Effect
Pharmacological activity is summarized：
All embodiments all show PI3K alpha kinases strong inhibitory activity, IC50Value is respectively less than 11nM.All implementations Example all shows human lung carcinoma cell NCI-H460 strong antiproliferative activity, IC50Value is respectively less than 4 μM.Wherein, embodiment 1 There is significant inhibiting effect in the growth of nude mice by subcutaneous heteroplastic transplantation knurl to human lung cancer NCI-H460.

Claims (10)

1. a kind of formula (I) compound represented, its stereoisomer, geometric isomer, tautomer or pharmaceutically acceptable Salt：
Wherein
R1For C1-3Alkyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R2Selected from hydrogen, C1-3Alkyl, C1-3Alkoxy, 3-7 members cycloalkyl or 3-7 membered heterocycloalkyls, wherein C1-3Alkyl, C1-3Alcoxyl Base, 3-7 members cycloalkyl or 3-7 membered heterocycloalkyls are optionally replaced by one or more Rb；
Rb is selected from halogen, cyano, hydroxyl, trifluoromethyl, C1-3Alkyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl amino or Two (C1-3Alkyl) amino；
R3Selected from C1-3Alkoxy, halogen or C1-3Alkyl；
R4Selected from C1-3Alkyl, 3-7 members cycloalkyl, aryl or heteroaryl, wherein the aryl and heteroaryl optionally by one or It is multiple to replace selected from following group：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, fluoroform Base, difluoromethyl, cyano or C1-3Alkoxy.
2. compound according to claim 1, its stereoisomer, geometric isomer, tautomer pharmaceutically may be used The salt of receiving, wherein the compound is formula (II) compound represented：
Wherein
R1Selected from C1-3Alkyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R3Selected from methoxyl group, chlorine or methyl；
R4Selected from C1-3Alkyl, 3-7 members cycloalkyl, phenyl or thienyl, wherein the phenyl and thienyl optionally by one or It is multiple to replace selected from following group：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, fluoroform Base, difluoromethyl, cyano or C1-3Alkoxy；
Ring A is selected from 3-7 members cycloalkyl or 3-7 membered heterocycloalkyls；
R5Selected from C1-3Alkyl, halogen, cyano, trifluoromethyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl amino or two (C1-3 Alkyl) amino；
M is 0,1,2,3 or 4；When m is 2,3 or 4, R5It can be identical or different group.
3. compound according to claim 2, its stereoisomer, geometric isomer, tautomer pharmaceutically may be used The salt of receiving：
Wherein
R1For methyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R3For methoxyl group；
R4Selected from phenyl or thienyl, wherein the phenyl and thienyl are optionally taken by one or more selected from following group Generation：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, trifluoromethyl, difluoromethyl, cyano or C1-3 Alkoxy；
Ring A is 3-7 member cycloalkyl；
R5Selected from C1-3Alkyl, halogen, cyano, trifluoromethyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl amino or two (C1-3 Alkyl) amino；
M is 0,1,2,3 or 4；When m is 2,3 or 4, R5It can be identical or different group.
4. compound according to claim 2, its stereoisomer, geometric isomer, tautomer pharmaceutically may be used The salt of receiving：
Wherein
R1For methyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R3For methoxyl group；
R4Selected from phenyl or thienyl, wherein the phenyl and thienyl are optionally taken by one or more selected from following group Generation：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, trifluoromethyl, difluoromethyl, cyano or C1-3 Alkoxy；
Ring A is 3-7 membered heterocycloalkyls；
R5Selected from C1-3Alkyl, halogen, cyano, trifluoromethyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl amino or two (C1-3 Alkyl) amino；
M is 0,1,2,3 or 4；When m is 2,3 or 4, R5It can be identical or different group.
5. compound according to claim 4, its stereoisomer, geometric isomer, tautomer pharmaceutically may be used The salt of receiving：
Wherein
R1For methyl；
L is selected from a singly-bound or C1-3Alkylidene, wherein the C1-3Alkylidene is optionally replaced by one or more Ra；
Ra is selected from halogen or C1-3Alkyl；
R3For methoxyl group；
R4Selected from phenyl or thienyl, wherein the phenyl and thienyl are optionally taken by one or more selected from following group Generation：Halogen, C1-3Alkyl, amino, C1-3Alkyl amino, two (C1-3Alkyl) amino, trifluoromethyl, difluoromethyl, cyano or C1-3 Alkoxy；
Ring A is selected from:
R5Selected from C1-3Alkyl, halogen, cyano, trifluoromethyl, C1-3Alkoxy, C1-3Hydroxy alkyl, C1-3Alkyl amino or two (C1-3 Alkyl) amino；
M is 0,1,2,3 or 4；When m is 2,3 or 4, R5It can be identical or different group.
6. according to claim 1-5 any one of them compound, its stereoisomer, geometric isomer, tautomer or Pharmaceutically acceptable salt, wherein compound are selected from：
7. a kind of pharmaceutical composition, it includes at least one compound according to any one of claim 1 to 6, it is vertical Body isomers, geometric isomer, tautomer or pharmaceutically acceptable salt and optional pharmaceutically acceptable carrier Or excipient.
8. pharmaceutical composition according to claim 7 is also included except the compound, its stereoisomer, geometry are different Active constituents of medicine except structure body, tautomer or pharmaceutically acceptable salt.
9. according to claim 1-6 any one of them compound, its stereoisomer, geometric isomer, tautomer or Pharmaceutically acceptable salt or pharmaceutical composition according to claim 7 or 8 are preparing for preventing and/or treat Purposes in the drug of the disease of PI3K mediations.
10. according to claim 1-6 any one of them compound, its stereoisomer, geometric isomer, tautomer or Pharmaceutically acceptable salt or pharmaceutical composition according to claim 7 or 8 are preparing for preventing and/or treat cancer Disease, immunity disease, angiocardiopathy, viral infection, inflammation, metabolism/endocrine dysfunction or neurological disease drug in Purposes.
CN201611214102.9A 2016-12-26 2016-12-26 Quinazoline compound, preparation method, application and pharmaceutical composition thereof Active CN108239076B (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
CN201611214102.9A CN108239076B (en) 2016-12-26 2016-12-26 Quinazoline compound, preparation method, application and pharmaceutical composition thereof
US16/473,901 US11534443B2 (en) 2016-12-26 2017-12-26 Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
AU2017389818A AU2017389818B2 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
EP17886474.0A EP3560921A4 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
PCT/CN2017/118771 WO2018121550A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
JP2019534817A JP7077323B2 (en) 2016-12-26 2017-12-26 Quinazoline compound and its preparation method, use and pharmaceutical composition
CN201780075753.0A CN110382490A (en) 2016-12-26 2017-12-26 Quinazoline compounds and preparation method thereof, purposes and pharmaceutical composition
CA3048546A CA3048546A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
EP22213594.9A EP4169918A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
CA3174865A CA3174865A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical composition thereof
CA3174890A CA3174890A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and its use as a phosphatidylinositol 3-kinase (pi3k) inhibitor
EP22213583.2A EP4169917A1 (en) 2016-12-26 2017-12-26 Quinazoline compound and preparation method, application, and pharmaceutical compostion thereof
AU2022202886A AU2022202886B2 (en) 2016-12-26 2022-04-30 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
AU2022202885A AU2022202885B2 (en) 2016-12-26 2022-04-30 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
JP2022081738A JP7384536B2 (en) 2016-12-26 2022-05-18 Quinazoline compounds and their preparation, use and pharmaceutical compositions
JP2022081736A JP7384535B2 (en) 2016-12-26 2022-05-18 Quinazoline compounds and their preparation, use and pharmaceutical compositions
US17/944,149 US20230110550A1 (en) 2016-12-26 2022-09-13 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof
US17/944,151 US20230113478A1 (en) 2016-12-26 2022-09-13 Quinazoline Compounds, Preparation Method, Use, and Pharmaceutical Composition Thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201611214102.9A CN108239076B (en) 2016-12-26 2016-12-26 Quinazoline compound, preparation method, application and pharmaceutical composition thereof

Publications (2)

Publication Number Publication Date
CN108239076A true CN108239076A (en) 2018-07-03
CN108239076B CN108239076B (en) 2021-07-06

Family

ID=62703927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201611214102.9A Active CN108239076B (en) 2016-12-26 2016-12-26 Quinazoline compound, preparation method, application and pharmaceutical composition thereof

Country Status (1)

Country Link
CN (1) CN108239076B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110382490A (en) * 2016-12-26 2019-10-25 中国医学科学院药物研究所 Quinazoline compounds and preparation method thereof, purposes and pharmaceutical composition
CN113620976A (en) * 2020-05-09 2021-11-09 中国医学科学院药物研究所 Thiazolopyrimidine compound and preparation method, application and pharmaceutical composition thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008157191A2 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Quinazoline derivatives as pi3 kinase inhibitors
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
WO2009055418A1 (en) * 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
CN101490016A (en) * 2006-07-28 2009-07-22 诺瓦提斯公司 2,4-substituted quinazolines as lipid kinase inhibitors
CN103153996A (en) * 2010-09-08 2013-06-12 Ucb医药有限公司 Quinoline and quinoxaline derivatives as kinase inhibitors
CN104093407A (en) * 2012-02-06 2014-10-08 葛兰素史克知识产权第二有限公司 Pi3k inhibitors for treating cough
CN104507933A (en) * 2012-05-31 2015-04-08 霍夫曼-拉罗奇有限公司 Aminoquinazoline and pyridopyrimidine derivatives
CN105283454A (en) * 2013-04-12 2016-01-27 阿萨纳生物科技有限责任公司 Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR pathways

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101490016A (en) * 2006-07-28 2009-07-22 诺瓦提斯公司 2,4-substituted quinazolines as lipid kinase inhibitors
WO2008157191A2 (en) * 2007-06-14 2008-12-24 Smithkline Beecham Corporation Quinazoline derivatives as pi3 kinase inhibitors
WO2009039140A1 (en) * 2007-09-17 2009-03-26 Smithkline Beecham Corporation Pyridopyrimidine derivatives as pi3 kinase inhibitors
WO2009055418A1 (en) * 2007-10-22 2009-04-30 Smithkline Beecham Corporation Pyridosulfonamide derivatives as pi3 kinase inhibitors
CN103153996A (en) * 2010-09-08 2013-06-12 Ucb医药有限公司 Quinoline and quinoxaline derivatives as kinase inhibitors
CN104093407A (en) * 2012-02-06 2014-10-08 葛兰素史克知识产权第二有限公司 Pi3k inhibitors for treating cough
CN104507933A (en) * 2012-05-31 2015-04-08 霍夫曼-拉罗奇有限公司 Aminoquinazoline and pyridopyrimidine derivatives
CN105283454A (en) * 2013-04-12 2016-01-27 阿萨纳生物科技有限责任公司 Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/MTOR pathways

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SONGWEN LIN, ET AL.: "Identification of novel 7-amino-5-methyl-1,6-naphthyridin-2(1H)-one derivatives as potent PI3K/mTOR dual inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *
YUAN-YUAN HEI, ET AL.: "Synthesis and antitumor activity evaluation of 4,6-disubstituted quinazoline derivatives as novel PI3K inhibitors", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110382490A (en) * 2016-12-26 2019-10-25 中国医学科学院药物研究所 Quinazoline compounds and preparation method thereof, purposes and pharmaceutical composition
US11534443B2 (en) 2016-12-26 2022-12-27 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof
CN113620976A (en) * 2020-05-09 2021-11-09 中国医学科学院药物研究所 Thiazolopyrimidine compound and preparation method, application and pharmaceutical composition thereof
CN113620976B (en) * 2020-05-09 2023-09-26 中国医学科学院药物研究所 Thiazolopyrimidine compound, preparation method, application and pharmaceutical composition thereof

Also Published As

Publication number Publication date
CN108239076B (en) 2021-07-06

Similar Documents

Publication Publication Date Title
JP7402549B2 (en) CXCR4 inhibitors and their uses
JP6994767B2 (en) CXCR4 inhibitor and its use
CN102971317B (en) Tetrahydro-pyridine also-pyrimidine derivatives
JP7084624B2 (en) CXCR4 inhibitor and its use
CN109311890A (en) BET protein degradation agent
CN112867721A (en) STING agonistic compounds
JP7384535B2 (en) Quinazoline compounds and their preparation, use and pharmaceutical compositions
BRPI0805826B1 (en) spiro-substituted compounds, pharmaceutical composition and use
CN103224496B (en) Tricyclic antidepressants PI3K and/or mTOR inhibitors
JP7323896B2 (en) Casein kinase 1ε inhibitor, pharmaceutical composition and use thereof
CN102361872A (en) Fused pyrimidines as AKT inhibitors
CN108239074B (en) Quinazoline compound, preparation method, application and pharmaceutical composition thereof
CN108239075A (en) Quinazoline compounds and preparation method thereof, purposes and pharmaceutical composition
CN104557871A (en) Arylmorpholine compounds with spiro substituents as well as preparation method and use thereof
CN108239076A (en) Quinazoline compounds and preparation method thereof, purposes and pharmaceutical composition
JP7036332B2 (en) Quinoline or quinazoline compounds and their applications
WO2023226176A1 (en) Thioamide derivatives, preparation method therefor, and use thereof
CN111936470A (en) Amidopyrazoles useful as FGFR irreversible inhibitors
CN111646973B (en) Polysubstituted quinazoline derivative and preparation method, pharmaceutical composition and application thereof
CN111362924B (en) Deuterated pyrimidine derivatives and uses thereof
CN111285806B (en) Pyrazole compound and preparation method, application and pharmaceutical composition thereof
CN112189009B (en) Chromene derivatives as inhibitors of TCR-NCK interactions
TWI557109B (en) Quinazoline compounds as kinase inhibitors and uses thereof
KR20230155351A (en) A kinase inhibitory compound containing 5-chloro-2,4-diaminopyrimidine, preparation therof and use thereof as anti-cancer agent comprising same
CN113620976A (en) Thiazolopyrimidine compound and preparation method, application and pharmaceutical composition thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant